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RESUMEN     El descubrimiento de los antibióticos a comienzos del siglo XX supuso una 
de las mayores revoluciones para la medicina moderna. Sin embargo, la euforia de 
haber superado el reto de las enfermedades infecciosas producidas por bacterias no 
duró mucho. Poco tiempo después de empezar a utilizarse los antibióticos, las 
bacterias comenzaron a desarrollar distintas formas de resistencia, hecho que se fue 
incrementando con el aumento del uso de los antibióticos. En la actualidad, la 
resistencia a antibióticos es una carrera de fondo en la que el descubrimiento de 
nuevas moléculas antibacterianas se ve superado por la velocidad de desarrollo de 
nuevos mecanismos de resistencia por parte de las bacterias. Por ello, la resistencia 
a antibióticos constituye un grave problema sanitario, tanto de Salud Pública como 
de Sanidad Animal, a escala mundial.  
 Los aminoglucósidos son una familia de antibióticos de gran relevancia 
clínica para el tratamiento de infecciones producidas por bacterias gram-positivas y 
gram-negativas, tanto en medicina humana como en medicina veterinaria. Su 
acción se basa en su unión a la subunidad ribosómica bacteriana 30S, en concreto 
al ARNr 16S en la región decodificante del sitio A, donde se comprueba la 
veracidad de la traducción. Como consecuencia la bacteria acumula proteínas 
erróneas lo que conlleva la muerte celular. La resistencia bacteriana a los 
aminoglucósidos se debe casi siempre a la producción de enzimas capaces de 
acetilar (acetiltransferasas), fosforilar (fosfotransferasas), o adenilar 
(nucleotidiltransferasas) el antibiótico inactivándolo. Cada enzima modificadora 
tiene especificidad por determinados aminoglucósidos, y aunque pueden suponer 
un problema en la práctica clínica, el nivel de resistencia que confieren no suele ser 
muy elevado. Adicionalmente se han descrito otros mecanismos de resistencia a 
aminoglucósidos, como la reducción de la concentración intracelular del 
antibiótico, o la modificación de la diana por mutaciones. No obstante, estos 
mecanismos no son muy significativos desde el punto de vista clínico. 
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  En 2003, sin embargo, se descubrió un nuevo mecanismo de resistencia a 
aminoglucósidos en bacterias gram-negativas. Este mecanismo consiste en la 
adición de un grupo metilo por parte de una enzima metiltransferasa en el ARNr 
16S, lo cual bloquea la unión del aminoglucósido al ribosoma. Esta 
metiltransferasa, denominada ArmA (Aminoglycoside resistance methyltransferase 
A), guarda homología con las metiltransferasas codificadas en el cromosoma de las 
bacterias ambientales productoras de aminoglucósidos. Estas bacterias, del orden 
Actinomycetales, metilan el ARNr 16S para evitar su propio suicidio por el 
antibiótico que producen. Además, las metiltransferasas del ARNr 16S adquiridas 
por bacterias gram-negativas se caracterizan por conferir un elevado nivel de 
resistencia a prácticamente todos los aminoglucósidos disponibles en la práctica 
clínica. Es por ello que su descubrimiento supuso una alarma para la Salud Pública, 
ante la posible pérdida de eficacia de una de las familias de antibióticos más 
relevantes tanto en medicina humana como medicina veterinaria.  
 Por este motivo, los objetivos de esta Tesis Doctoral son la identificación 
de metiltransferasas de resistencia a aminoglucósidos en bacterias gram-negativas 
de distinto origen, y la caracterización molecular de dichas cepas así como de las 
plataformas genéticas implicadas en su  transmisión.   
 Este trabajo consta de cuatro publicaciones con las cuales hemos 
contribuido a un mayor conocimiento sobre la presencia y la diseminación de las 
metiltransferasas del ARNr 16S en bacterias gram-negativas de origen humano, 
animal y alimentario.  
 Por un lado, hemos detectado por primera vez la presencia de ArmA, la 
metiltransferasa más prevalente hasta ahora, en una cepa aislada de alimento. Esta 
cepa se aisló en la Isla de Reunión y se identificó como Salmonella enterica 
1.4,12:i:−, una variante monofásica de S. enterica Typhimurium. Se observó que 
portaba la isla genómica 1 de Salmonella (SGI1), y tres plásmidos que 
denominamos pB1008, pB1009, y pB1010. Los plásmidos pB1008 y pB1010 se 
transfirieron por conjugación a una cepa receptora de laboratorio, E. coli K802N. 
Las frecuencias de conjugación de pB1008 y pB1010 fueron 4 × 10−4  y 9 × 10−4  
UFC por donadora, respectivamente, aunque ambos plásmidos se transfieren 
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conjuntamente con una frecuencia de 10−5.  El análisis de distintos determinantes 
de resistencia reveló la presencia de los genes blaCMY-2 en pB1008, y armA y 
blaCTX-M-3 en pB1010. La técnica de digestión con nucleasa S1 y PFGE permitió 
comprobar que el tamaño de los plásmidos pB1008 y pB1010 era 50 kb y 110 kb, 
respectivamente. Además, la clasificación de los plásmidos siguiendo un protocolo 
de tipado por PCR reveló que pB1010 pertenecía al grupo de incompatibilidad 
IncP, mientras que pB1008 y pB1009 no eran tipables siguiendo esta metodología. 
Por otro lado, se desarrolló un sistema de 9 PCRs para amplificar el Tn1548, la 
plataforma genética en la cual armA se había visto ubicado previamente, y se 
comprobó la presencia de armA en un derivado de Tn1548.  
 En otra de las publicaciones hemos identificado ArmA en cepas de S. 
enterica serovars Thompson y Worthington de origen clínico aisladas en Reino 
Unido. En este caso observamos que armA está localizado en dos plásmidos 
conjugativos, pB1015 en S. Thompson, y pB1016 en S. Worthington. pB1015 es un 
plásmido IncHI2 de 245 kb, mientras que pB1016 es un plásmido IncA/C de 170 
kb, que, además de armA, codificaba el gen de la beta-lactamasa CMY-2, y el gen 
de una nueva BLEE de tipo VEB que denominamos blaVEB-5. Este último confiere 
resistencia a cefalosporinas de 3ª generación y a aztreonam. El mapeo por PCR de 
Tn1548 nos permitió comprobar cómo distintas variantes genéticas de este 
transposón parecen estar implicadas en la diseminación de armA.  
 La tercera publicación comprende un estudio de la presencia de estas 
metiltransferasas en aislados clínicos de India. Se analizaron 1000 aislados 
consecutivos de enterobacterias, observándose altos niveles de resistencia a 
aminoglucósidos en el 14% (140 aislados). Identificamos ArmA, RmtB, y RmtC 
por PCR en el 46%, 20%, y 27% de estos 140 aislados. Mediante ensayos de 
clonaje y posterior secuenciación, descubrimos un nuevo miembro de la familia de 
las metiltransferasas del ARNr 16S que confieren resistencia a aminoglucósidos, 
RmtF, en 34 de estas cepas. Esta nueva metiltransferasa comparte la mayor 
identidad en aminoácidos con RmtD (46%), y confirmamos mediante 
espectrometría de masas MALDI que confiere alto nivel de resistencia a 
aminoglucósidos mediante la adición de un grupo metilo en posición G1405 del 
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ARNr 16S. rmtF se encontró localizado en distintos plásmidos, la mayoría de ellos 
transferibles, y el 59% de las cepas productoras de rmtF portaban la carbapenemasa 
NDM. Además, rmtF se detectó en seis cepas clínicas productoras de NDM-1 
aisladas en Reino Unido.  
 Por último, hemos detectado ArmA por primera vez en cepas procedentes 
de animales de compañía. Se trata de siete Klebsiella pneumoniae aisladas de 
perros y gatos en España. Tras su caracterización mediante MLST comprobamos 
que todas ellas son K. pneumoniae ST11, un clon epidémico adaptado a humanos y 
previamente descrito en España asociado a determinantes de resistencia 
emergentes, lo cual muestra el alarmante papel que pueden representar los animales 
de compañía como reservorios de estos mecanismos de resistencia. En estos 
aislados, armA está en pB1025, un plásmido IncR de 50 kb. Esta es la primera 
descripción de un plásmido IncR en bacterias aisladas de animales de compañía. 
Dichos aislados también co-producen las β-lactamasas DHA-1 y SHV-11, y el 
determinante de resistencia a fluoroquinolonas QnrB4. 
 En conclusión, esta Tesis Doctoral contribuye a un mayor conocimiento 
sobre uno de los mecanismos de resistencia a antibióticos más novedosos, las 
metiltransferasas del ARNr 16S, así como analiza las interrelaciones humano-
animal-alimento en su dinámica propagación.  
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SUMMARY 
 
 The discovery of antibiotics at the beginning of the 20th century constituted 
one of the biggest revolutions in modern medicine. However, the euphoric feeling 
of overcoming the challenge of bacterial-caused diseases did not last. Shortly after 
the initiation of antibiotics use, bacteria started to develop diverse ways of 
resistance, so the higher usage of antibiotics, the higher incidence of resistant 
bacteria. Nowadays, antibiotic resistance is a race where the development of 
bacterial resistance mechanisms is faster than the discovery of new antibacterial 
molecules. Not for nothing, antibiotic resistance poses a serious global problem, for 
both Public and Animal Health.       
 Aminoglycosides are a family of antibiotics very important in human and 
veterinary medicine for the treatment of infections caused by gram-positive and 
gram-negative bacteria. They bind to the bacterial 16S rRNA in the 30S ribosomal 
subunit, specifically at the point where the fidelity of translation is verified. This 
binding causes the accumulation of erroneous proteins, leading to the cell death. 
Bacterial resistance to these antibiotics is generally due to the production of 
enzymes that are able to acetylate (acetyltransferases), phosphorylate 
(phosphotransferases), or adenylate (nucleotidyltransferases) the antibiotic 
molecule, thus making it inactive. Every modifying enzyme shows specificity for 
certain aminoglycosides, and even though they can represent a problem in clinical 
settings, they do not usually confer high levels of resistance. Additionally, other 
aminoglycoside resistance mechanisms have been described, such as the reduction 
of the intracellular concentration of antibiotic, or the target modification by 
mutation. Nevertheless, these mechanisms are not highly significant from a clinical 
point of view.  
 In 2003, however, a new aminoglycoside resistance mechanism was 
discovered in gram-negative bacteria. It consists on the addition of a methyl group 
to the 16S rRNA by a methyltransferase enzyme, which blocks the aminoglycoside 
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binding to the ribosome. This protein, named ArmA (Aminoglycoside resistance 
methyltrasnferase A), shares homology with those methyltransferases encoded in 
the chromosome of aminoglycoside-producing environmental bacteria. These 
bacteria, belonging to the Actinomycetales, methylate the 16S rRNA in order to 
avoid their suicide by the antibiotic that they generate. Furthermore, acquired 16S 
rRNA methyltrasferases in gram-negative bacteria confer high-level resistance to 
almost all aminoglycosides available in the clinical practice. Therefore, their 
discovery posed a threat for the Public Health, facing the likely loss of efficacy of 
one of the most relevant antibiotic families for human and veterinary medicine.  
 For this reason, the objectives of this Doctoral Thesis are the identification 
and molecular characterization of aminoglycoside resistance methyltransferases in 
gram-negative bacteria from diverse origins, as well as the analysis of the genetic 
platforms involved in their transmission.     
 This work is constituted by four publications that have contributed to a 
deeper knowledge about the presence and spread of the 16S rRNA 
methyltransferases in gram-negative bacteria from humans, animals, and food.  
 On one side, we have detected for the first time ArmA, the most prevalent 
methyltransferase thus far, in a strain isolated from food. This strain, isolated in La 
Reunion Island, was identified as Salmonella enterica 1.4,12:i:−, a monophasic 
variant of S. enterica Typhimurium. It was observed the presence of Salmonella 
genomic island 1 (SGI1), as well as three plasmids named pB1008, pB1009, and 
pB1010. Plasmids pB1008 and pB1010 were transferred by conjugation to a 
laboratory recipient strain, E. coli K802N. The conjugation frequencies for pB1008 
and pB1010 were 4 × 10−4  and 9 × 10−4  per donor CFU, respectively, and both 
plasmids were cotransferred at a frequency of  10−5 per donor CFU. The analysis of 
several resistance determinants revealed the presence of  blaCMY-2 in pB1008, and 
armA and blaCTX-M-3 in pB1010. S1-nuclease digestion and PFGE allowed to 
determine that plasmids pB1008 and pB1010 were 50 kb and 110 kb in size, 
respectively. Moreover, plasmid PCR-based replicon typing showed that pB1010 
belongs to the IncP incompatibility group, whereas pB1008 and pB1009 are non-
typable following this methodology. Furthermore, we developed a system based on 
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9 overlapping PCRs to amplify the Tn1548, the genetic platform where armA had 
been previously identified, and it was observed to be embedded in a Tn1548 
derivative.  
 In another publication we have identified ArmA in clinical S. enterica 
serovars Thompson and Worthington isolated in the United Kingdom. In this case, 
armA is located on two conjugative plasmids, pB1015 in S. Thompson, and 
pB1016 in S. Worthington. pB1015 is an IncHI2 plasmid of 245 kb, whereas 
pB1016, sized 170 kb, belongs to the IncA/C group, and, besides armA, it bears 
blaCMY-2, and a novel VEB ESBL gene, called blaVEB-5. The latter confers 
resistance to 3rd generation cephalosporins and aztreonam. Tn1548 mapping 
showed how different variants of this transposon are involved in the dissemination 
of armA.  
 The third publication comprises a prevalence study of this 
methyltransferases in clinical isolates from India. We analyzed 1000 consecutive 
Enterobacteriaceae isolates, and we observed high-level aminoglycoside resistance 
in the 14% (140 isolates). Out of these, we identified by PCR ArmA, RmtB, and 
RmtC in the 46%, 20%, and 27%, respectively. After cloning experiments and 
subsequent sequencing, we discovered a new member of the aminoglycoside 
resistance 16S rRNA methyltransferases family, RmtF, in 34 strains. This novel 
methyltransferase shares the highest amino acid identity with RmtD (46%), and we 
confirmed by MALDI mass spectrometry that it confers high-level aminoglycoside 
resistance by specifically adding a methyl group at position G1405 in the 16S 
rRNA. rmtF was found located on diverse plasmids, most of them transferable by 
electroporation, and 59% of rmtF-producing strains also carried NDM 
carbapenemase. In addition, rmtF was detected in six clinical NDM-producing 
strains isolated from the UK.  
 Finally, we have described ArmA for the first time in bacteria from 
companion animals. It was identified in seven K. pneumoniae isolates from dogs 
and cats in Spain. MLST characterization showed that all of them are K. 
pneumoniae ST11, a human epidemic clone previously reported in Spain in 
association with emerging resistance determinants. This is worrisome as it implies 
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companion animals may be a reservoir for these resistance mechanisms. In these 
isolates, armA is borne by pB1025, and IncR plasmid of 50 kb. To the best of our 
knowledge, this is the first report of an IncR plasmid in bacteria from pets. The 
isolates also co-produce β-lactamases DHA-1 and SHV-11, and the 
fluoroquinolone resistance determinant QnrB4.  
 Overall, this Doctoral Thesis has contributed to a better understanding of an 
emerging antibiotic resistance mechanism, the 16S rRNA methyltransferases, as 
well as it has analyzed the interrelations human-animal-food in their rapid spread.             
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INTRODUCTION 
 
CHAPTER 1. Aminoglycoside antibiotics 
 
1.1- Historical aspects  
 After the discovery of penicillin as an antibacterial substance produced by 
Penicillium rubens, and attributed to Alexander Fleming in 1928, the 
aminoglycosides were the first important therapeutic agents produced by bacterial 
fermentation.  In 1944, Albert Schatz and Selman Waksman discovered 
streptomycin by screening different cultures of soil bacteria for the presence of 
inhibitory activity against M. tuberculosis (Schatz et al., 1944). This molecule was 
produced by the actinobacterium Streptomyces griseus, and it became the first 
antibiotic effective against tuberculosis. For this discovery S. Waksman was 
awarded the Nobel Prize in Medicine in 1952. The second aminoglycoside, 
neomycin, was reported in 1949, but its toxicity issues coupled with the emerging 
resistance to streptomycin gave rise to additional aminoglycosides discoveries in 
the 1950s and early 1960s (Jana and Deb, 2006), including kanamycin (produced 
by Streptomyces kanamyceticus) and gentamicin (isolated from Micromonospora 
purpurea). But the increasing appearance of resistant strains producing enzymes 
capable of modifying the antibiotic molecule led to the search for novel 
synthesized aminoglycoside derivatives (Kondo, 1999). Thus, in 1975, dibekacin 
was approved for therapeutic use as the first designed semisynthetic 
aminoglycoside. Arbekacin, a kanamycin B semisynthetic derivative, is the most 
recent aminoglycoside introduced for antibacterial therapy in the 1990s in Japan 
(Jana and Deb, 2006).  
 Most aminoglycosides discovered to date are produced by Actinobacteria of 
either the genus Streptomyces or Micromonospora. Aminoglycosides that are 
derived from Streptomyces are named with the suffix –mycin (e.g. streptomycin, 
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neomycin or kanamycin) whereas those derived from Micromonospora are named 
with the suffix –micin (e.g. gentamicin or sisomicin).   
 
1.2- Mechanism of action 
 The major target of aminoglycosides is the bacterial 30S subunit (Figure 1). 
They bind to the A-site (Aminoacyl site) tRNA acceptor which is part of the 16S 
rRNA, leading to a loss of translational accuracy and subsequently, to the cell 
death (Jana and Deb, 2006). Biochemical and molecular biological approaches, as 
well as studies based on nuclear magnetic resonance (NMR) and X-ray crystal 
structures, have identified the basis for aminoglycoside binding to bacterial 
ribosomes (Magnet and Blanchard, 2005).  
 
 
Figure 1. Schematic representation of the bacterial ribosome and an enlarged view of the 
aminoglycosides binding to the A site, showing the interactions between the antibiotic 
molecule and the respective residues. A: tobramycin (2-DOS), B: streptomycin (no 2-DOS). 
Adapted from Magnet and Blanchard, 2005.     
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 Although aminoglycosides bind electrostatically to the outer membrane of 
gram-negative bacteria or to the exterior of the cell wall of gram-positive bacteria, 
in a non-energy dependent process, their uptake and diffusion across the 
cytoplasmic membrane requires energy generated from an oxygen-dependent 
process, called energy dependent phase I (EDP-I) (Taber et al., 1987). As a 
consequence, these antibiotics are less active in anaerobic conditions. 
Aminoglycoside uptake is a self-promoted process that requires a proton-motive 
force and involves a drug-induced disruption of Mg2+ bridges between adjacent 
lipopolysaccharide molecules (Mingeot-Leclerq et al., 1999). Once in the cytosol, 
aminoglycosides bind to the A-site in the small subunit of the ribosomes through 
an energy-dependent process called energy dependent phase II (EDP-II) (Magnet 
and Blanchard, 2005). The A site is comprised of, amongst others, a portion of 
helix 44. As it has been extensively described, the fidelity of translation depends 
mainly on the correct formation of the initiation complex, which involves the 
mRNA codon and the appropriate tRNA anticodon, and the subsequent 
proofreading during the elongation step. When a cognate tRNA-mRNA complex is 
formed, residues A1492 and A1493 are flipped out from helix 44, and this 
configuration allows the discrimination between correct or erroneous complexes 
(Carter et al., 2000).  Aminoglycoside binding takes place in a pocket formed by 
various residues of helix 44 which are universally conserved nucleotides A1492 
and A1493, and the prokaryotic-specific nucleotide A1408. This aids in their 
selective activity against the bacterial as opposed to the eukaryotic ribosome (Jana 
and Deb, 2006).  
 It has been biochemically elucidated that when a 2-deoxystreptamine (2-
DOS) aminoglycoside binds to this pocket, it causes a flip out of residues A1492 
and A1493 similar to that which occurs when there is a cognate mRNA-tRNA 
complex. Therefore, there is no discrimination between cognate and non-cognate 
complexes, which disrupts the translation at the elongation level leading to the 
accumulation of aberrant proteins. These may be inserted into the cell membrane, 
altering the permeability and even increasing the aminoglycoside transport (Carter 
et al., 2000).  
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 Regarding the specific mechanism of atypical aminoglycosides (non 2-
DOS), the interaction of three of them (streptomycin, spectinomycin, and 
hygromycin B) with the 30S subunit has been studied at a biochemical level. 
Streptomycin binds to the A site, however, in contrast to the 2-DOS-
aminoglycosides, it does not interact only with residues from helix 44 but also with 
residues from adjacent domains. It had been previously proposed that an interaction 
between helix 27 and helix 44 leads to two different ribosomal conformations and 
the equilibrium of which could be involved in the translational proofreading. 
Therefore, the binding of streptomycin appears to interfere with that balance. The 
binding of both spectinomycin and hygromycin B to the 30S subunit inhibits the 
translocation of the peptidyl-tRNA from the A site to the P site (Peptidyl site), 
although hygromycin B also causes miscoding at a lower level than DOS-
aminoglycosides  (Carter et al., 2000).   
 Besides the 30S ribosomal subunit as the major target of aminoglycosides, 
it has been recently shown that some aminoglycosides, such as gentamicin and 
neomycin, bind to helix 69 of the 23S rRNA in the large subunit. Binding at this 
site inhibits the ribosomal recycling process, a necessary step in which the two 
subunits separate from each other after the termination phase of protein synthesis 
(Wang et al., 2012).   
  
1.3- Properties and nomenclature 
 The broad-spectrum of aminoglycosides as well as their pharmacokinetics 
and potency is tightly related to their chemical properties. They are metabolically 
stable so they are excreted unmodified by the organism. Aminoglycosides are 
hydrophilic molecules, relatively insoluble in lipids, and they show an increased 
activity under alkaline conditions. These characteristics explain their poor 
absorption from the gut and the minimal penetration of the blood brain barrier. 
Aminoglycosides are positively charged (cationic), thus, they are able to bind to 
different cell membranes and intracellular anionic molecules (phospholipids, DNA, 
RNA). Nevertheless, this cationic nature contributes to their toxicity at 
physiological pH (Vincens and Westhof, 2002).   
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1.3.1- Chemical structure 
 The term “aminoglycoside” is given due to the general chemical structure 
of this group of antimicrobial agents. The backbone consists of an aminocyclitol 
ring that can be saturated with amine and hydroxyl substitutions, and it is linked to 
one or more amino sugars through glycosidic linkages (Benvetiste and Davies, 
1973). In the case of spectinomycin, there is no amino sugar linked to the ring, 
therefore, various scientists have suggested that this group of agents should be 
described by the term “aminocyclitols” instead of “aminoglycosides” (Jana and 
Deb, 2006). The aminocyclitol core is the 2-deoxystreptamine in most 
aminoglycosides important for chemotherapy (Figure 2), and it can be 
monosubstituted in position 4, or disubstituted in positions 4 and 5, or 4 and 6. 
Nevertheless, there are other aminocyclitol rings that constitute the aminoglycoside 
structure, such as streptamine, actinamine, or fortamine.  It has been extensively 
shown that the number and location of amino groups in the sugars attached to the 
ring profoundly affect the biological activity of the antibiotic (Vincens and 
Westhof, 2002). The presence of at least one amino group in these sugars is 
required for the biological activity, and the addition of extra substituents to the 
aminocyclitol-aminosugar (e.g. ribose moiety in the case of ribostamycin) can 
further increase the activity of these compounds.  
 More than 150 naturally-occurring aminogycosides have been isolated from 
Actinobacteria cultures to date, but it is the structural core that divides this group of 
antibiotic agents into two subgroups commonly called typical or atypical 
aminoglycosides. Typical aminoglycosides would be those consisting of a 2-
deoxystreptamine as the aminocyclitol moiety and are the most commonly used for 
therapeutic purpose. Although we will find aminoglycosides mostly divided into 2-
DOS and non-2-DOS, we may find literature classifying aminoglycosides into 
three structural groups based on the position of the glycosidic bonds. These groups 
are the 4,6-disubstituted 2-deoxystreptamines, the 4,5-disubstituted 2-
deoxystreptamines, and others. It is remarkable that aminoglycosides within a 
certain class differ from each other in subtle ways. The main features of different 
aminoglycoside antibiotics are outlined in Table 1.  
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Figure 2. Chemical structure of a selection of 2-DOS aminoglycosides. Vincens and Westhof, 
2002.  
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1.3.1.1- 2-DOS aminoglycosides  
 The aminoglycosides composed of a 2-DOS core can be substituted at the 
C4, C5, and C6 position. The 4,5-disubstituted 2-DOS are represented by the 
neomycins, firstly described in 1949 and produced by different members of the 
genus Streptomyces. This family includes a variety of different naturally-occurring 
compounds. Ribostamycin has been described as a common precursor of all other 
family members: neomycins, paromomycins, lividomycins, and butirosins. Some 
Micromonospora spp. have been found to produce neomycins and paromomycins. 
Interestingly, butirosin can be produced by species of the genus Bacillus.  
 The 4,6-disubstituted 2-DOS class contains most of the clinically useful 
aminoglycosides, and some of the members of this group have been used as a 
template for the design of new semisynthetic agents (Park et al., 2013). Two 
families can be found in this group. The kanamycin family, firstly described in 
1957 from a S. kanamyceticus culture, includes the naturally-produced compounds 
kanamycin, bekanamycin, and tobramycin; and this family has led to the creation 
of dibekacin, amikacin, and arbekacin as semisynthetic derivatives. The other 
subfamily is constituted by the gentamicins. These agents were first isolated from 
cultures of M. purpurea (which was later renamed to M. echinospora), in 1963. 
Very similar compounds were described later from cultures of other species of 
Micromonospora spp. The main naturally-produced aminoglycosides related to 
gentamicin are gentamicin C, gentamicin B, micronomicin, sisomicin, and 
geneticin. Netilmicin and isepamicin are semisynthetic derivatives that belong to 
this group (Magnet and Blanchard, 2005). Although the 2-DOS aminoglycosides 
are generally disubstituted in positions 4 and 5, or 4 and 6 as described above, there 
is one structurally unique aminoglycoside belonging to this group: apramycin. This 
compound´s aminocyclitol is also 2-deoxystreptamine but it is monosubstituted in 
position 4, and it is produced by various actinomycetes of the Streptomyces genus 
but also to other genera such as Sacchalopolyspora (Matt et al., 2013).     
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1.3.1.2- Non 2-DOS aminoglycosides 
 This group represents a minority of the total of aminoglycoside compounds 
discovered to date, and the agents belonging to this group are not as clinically 
relevant as the 2-DOS aminoglycosides, with the sole exception of streptomycin. 
The main representative antibiotics of this group are streptomycin, spectinomycin 
and fortimicin (Piepersberg, 1995). Streptomycin possesses a streptidine ring as the 
central aminocyclitol, with a glycosidic substitution in position 4. Spectinomycin, 
Table 1. General features of the most relevant aminoglycoside antibiotics 
Aminoglycoside Aminocyclitol  
Naturally-
produced 
(N)/Semisynthetic 
(S) 
Origin Discovery 
Gentamicin N M. purpurea 1963 
Sisomicin N M. inyoensis 1970 
Isepamicin S  Gentamicin derivative 1974 
Netilmicin S  Sisomicin derivative 1975 
Kanamycin N S. kanamyceticus 1957 
Tobramycin N S. tenebrarius 1967 
Dibekacin S  Bekanamycin derivative 1971 
Amikacin S  Kanamycin derivative 1972 
Arbekacin 
2-DOS (4,6-
disubstituted) 
S  Bekanamycin derivative 1973 
Neomycin 2-DOS (4,5-disubstituted) N S. fradiae 1949 
Apramycin 2-DOS (4-monosubstituted) N S. tenebrarius 1968 
Streptomycin streptidine N S. griseus 1944 
Spectinomycin actinamine N S. spectabilis 1961 
Fortimicin fortamine N M. olivasterospora 1977 
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detected from Streptomyces spectabilis in 1961, does not contain an amino sugar as 
mentioned before. Instead, it is composed of an aminocyclitol designated 
actinamine, and actinospectose. Finally, fortimicins (also called astromicins), have 
firstly been described in cultures of Micromonospora olivasterospora, in 1977. 
Later, very similar compounds were found to be produced in other actinomycete 
genera and species (as is the case of dactimicin from Dactylosporangium 
matsuzakiense). The fortimicins contain an aminocyclitol called fortamine.   
 
1.4- Therapeutic traits and applications 
 Aminoglycosides exhibit bactericidal activity and they can be considered as 
broad-spectrum antimicrobials. Only spectinomycin and kasugamycin, two 
inhibitors of the translocation step, act bacteriostatically. The action of this group 
of antibiotic agents is concentration-dependent. The 4,5- and 4,6-disubstituted 2-
DOS are the most important aminoglycosides in terms of clinical therapy. 
Nevertheless, the growing problem of antibiotic resistance is forcing the urgent 
discovery or synthesis of new molecules, and for that purpose a detailed 
understanding of the biosynthetic pathways of aminoglycosides is crucial (Park et 
al., 2013). Although the biosynthetic pathways of the 4,5-disubstituted 2-DOS have 
been elucidated (Kudo and Eguchi, 2009), those of the 4,6-disubstituted 2-DOS 
remain unclear, with the sole exception of the recent ascertainment of the 
kanamycin biosynthetic pathway (Park et al., 2011). This finding, combined with 
the engineered synthesis of an active kanamycin analogue, proves that a potential 
formulation of more powerful aminoglycosides is possible. Unfortunately, it is well 
known that certain aminoglycosides do not only display activity on the 70S 
ribosomes of prokaryotes, but also on the 80S ribosomes of eukaryotes, leading to 
significant toxicity issues and secondary effects when used, which will be further 
described in this chapter.  Among the advantages of the aminoglycosides, we could 
highlight their chemical stability, as well as their rapid and broad-spectrum 
bactericidal action, the rarity of allergic reactions, the low cost compared to other 
agents, and the possibility of synergistic activity in a combined therapy with other 
antibiotics. On the other hand, aminoglycosides entail some disadvantages such as 
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the poor oral absorption, the inactivity against anaerobic bacteria, and most 
importantly, the different toxicities that they exhibit. The main applications of 
different aminoglycosides are listed in Table 2.   
 
1.4.1- Clinical use    
 Most aminoglycosides exhibit a strong activity against a wide range of 
mainly aerobic gram-negative bacteria, including Pseudomonas spp., and they can 
also display antibactericidal action on certain mycobacteria and staphylococci 
(Davies, 2006). They have a poor efficacy against streptococci and they rarely 
inhibit the growth of anaerobic bacteria. As it has been explained before, and due 
to their cationic nature, aminoglycosides are poorly absorbed orally. For this 
reason, and in order to reach the optimal serum concentrations, as a rule they are 
administered parenterally (Edson and Terrel, 1999). Although during the last 20 
years, aminoglycosides have been largely replaced by new generations of 
antibiotics such as cephalosporins, they are still widely used, remaining one of the 
major groups of antibiotics in chemotherapy, as stated by the World Health 
Organization (WHO, 2007). This family of antibiotics is especially useful to treat 
serious infections due to aerobic gram-negative bacteria, as well as they are a 
nearly ideal therapy for emergencies because of their broad spectrum and lack of 
allergic reactions.  
 The main aminoglycoside molecules available as chemotherapeutic agents 
are streptomycin, spectinomycin, neomycins, paromomycins, ribostamycin, 
kanamycin, bekanamycin, gentamicins, sisomicin, micronomicin, tobramycin, and 
fortimicin. In addition, five semisynthetic aminoglycosides were initially marketed 
as chemotherapeutic agents to combat aminoglycoside-resistant bacteria. These are 
netilmicin, isepamicin, amikacin, dibekacin, and arbekacin.  
 In current clinical practice, gentamicin, tobramycin, and amikacin are often 
used interchangeably as the agents of choice for the treatment of hospital acquired 
infections caused by Enterobacteriaceae and Pseudomonas aeruginosa.  Perhaps 
gentamicin is the aminoglycoside most commonly used due to its low cost and 
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excellent activity against gram-negative aerobic bacteria. Tobramycin has shown 
an increased in vitro activity against P. aeruginosa in several studies, but whether 
this action would be significant or not in vivo has been questioned. The 
semisynthetic amikacin became an effective alternative when it was used against 
resistant bacteria due to modifying enzymes, as its chemical structure was 
developed to make it less susceptible to such modifications. Streptomycin, which 
was the first effective treatment for tuberculosis, is still the agent of choice to treat 
multi-drug resistant Mycobacterium tuberculosis. It is also used against tularemia 
(Francisella tularensis), and the plague (Yersinia pestis); and it could be an 
alternative treatment for brucellosis. Neomycin and paromoycin are mainly used 
topically for various applications, such as ulcers, wounds, or burns. The newest 
semisynthetic aminoglycoside, arbekacin, which is not a substrate for many 
aminoglycoside-modifying enzymes, became very popular in the 1990s in Japan 
for the treatment of infections caused by gentamicin-resistant bacteria. However, as 
will be further described through out this thesis, the appearance of 16S rRNA 
methyltransferases as a high-level resistance mechanism, led to a lack of 
effectiveness of most aminoglycosides including arbekacin in strains bearing a 16S 
rRNA methyltransferase. Nevertheless, the development of arbekacin brought an 
effective treatment for infections due to methicillin-resistant S. aureus (MRSA) 
(Davies, 2006).  
 The conventional dosing for gentamicin, tobramycin, or netilmicin is 
approximately 5 mg/kg per day, but some other aminoglycosides may require 
higher doses, as it is the case of amikacin or streptomycin. Generally, the accepted 
therapeutic concentration required for the inhibition of prokaryotic protein 
synthesis is ≤ 25 µg/ml for clinically used aminoglycosides. Regarding single 
versus multiple daily doses, it has been reported that the obtained efficacy of a 
single daily dose is similar, since aminoglycoside activity is concentration-
dependent and effects are visible at a later stage (Freeman et al., 1997). This can be 
favourable because a single dose means less toxicity, lower cost, and reduced 
selection of resistant bacterial populations. In addition, it has been proved that 
single daily dosing is more beneficial for patients, as long as they have normal 
renal activity. Despite these findings, the conventionally recommended therapy 
Introduction 
[Pick the date]  
  36 
involves multiple doses per day. Further observations have shown that, although 
aminoglycosides are commonly administered by either an intravenous or 
intramuscular route, liposome-encapsulated or aerosolized aminoglycosides can be 
favourable against intracellular Mycobacterium avium or to treat respiratory tract 
infections. Occasionally, it is recommended to use a rotation of aminoglycosides in 
order to avoid treatment failures due to resistant strains.   
 One of the great advantages of aminoglycosides is the possibility of a 
combined therapy with other antibiotics that lead to a synergistic bactericidal effect 
due to an increased uptake of aminoglycosides by the bacterial cells. Routinely, the 
combination used for the treatment of serious nosocomial infections consists of 
gentamicin and a β-lactam, usually ampicillin. Nevertheless, other antibiotics that 
inhibit cell wall synthesis can be co-administered with an aminoglycoside to 
improve the therapy against bacteria naturally resistant to aminoglycosides due to a 
reduced uptake. With respect to urinary tract infections (one of the clinical targets 
of aminoglycosides) these antibiotics can be used without combined therapy, 
giving rise to a desirable efficacy.  
 
1.4.1.1-Aminoglycosides in Veterinary Medicine 
 The use of aminoglycosides in the treatment of infections in animals has 
been moderated and it can vary depending on toxicity considerations regarding the 
animal treated. Furthermore, the toxicity concerns during long-term therapies have 
further limited the usefulness of aminoglycosides. Often, systemic use is limited to 
the treatment of serious gram-negative infections resistant to less toxic medication.  
Since the use of antibiotics as growth promoters was banned in the European 
Union in 2006, aminoglycosides can be employed only for clinical purposes in 
different animal species, including both food producing animals and companion 
animals.  
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Table 2. Main applications of aminoglycosides 
Aminoglycoside Use 
Gentamicin 
Amikacin 
Tobramycin 
 
- hospital acquired 
infections 
- P. aeruginosa infections 
 
Streptomycin 
- MDR M.tuberculosis 
- tularemia 
- plague 
Neomycin 
Paromomycin 
- Topical use (ulcers, 
burns..) 
Arbekacin - MRSA 
 Bactericidal in 
human 
medicine 
  
  
Neomycin 
- oral administration for 
enteritis in food 
producing animals  
Gentamicin 
Amikacin 
- Respiratory/urinary tract 
infections and 
septicemias in companion 
animals  
Streptomycin 
Dihydrostreptomycin 
- staphylococci 
- Pasteurella spp. 
- Brucella spp. 
- Leptospira spp. 
- tuberculosis 
Apramycin 
- colibacillosis and 
salmonellosis in calves 
and lambs 
- enteritis in pigs and 
rabbits 
- septicemia in poultry  
 Bactericidal in 
veterinary 
medicine 
  
Destomycin A 
Hygromycin B 
- anthemintics in animals 
6´-OH AGs - human genetic diseases 
Paromomycin 
Ribostamycin 
Kasugamycin 
- prevention of plant 
diseases 
Others 
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 The approval of certain aminoglycosides for veterinary medicine is 
regulated depending on the current legislation of each country, therefore, there is a 
worldwide variation of the use of each aminoglycoside as an authorized antibiotic 
for veterinary medicine. In the same way, regulatory requirements concerning 
withdrawal times for food animals as well as milk discard times vary among 
countries. It is important to take into account, that according to the type of 
production and number of animals, sometimes the treatments are not individual as 
they are in companion animals. So when large groups of animals have to be treated, 
such as in poultry or swine production, the compound has to be applied via the feed 
or the water. This is a disadvantage for aminoglycosides due to their poor oral 
absorption. In general, the most commonly used aminoglycosides in veterinary 
medicine are gentamicin, neomycin, streptomycin and dihydrostreptomycin. 
Neomycin is usually administered as an oral solution for all food producing species 
to control enteritis caused mainly by Escherichia coli, whereas injections of 
gentamicin or amikacin are lisenced for the treatment of septicemia, respiratory and 
urinary tract infections, or other serious infections in animals not used for food 
production, such as dogs and cats. In minor species, such as parrots, ball pythons, 
gophers, tortoises, or guinea pigs; the safety and efficacy have not yet been 
established, however, both gentamicin and amikacin are recommended for the 
treatment of certain bacterial infections, as long as the treated animals are not used 
for food production. Streptomycin and dihydrostreptomycin (no longer available in 
the USA) are characterized by a narrow spectrum, and their efficacy is more 
limited by bacterial  resistance. They are mainly used against staphylococci, 
Pasteurella spp., Brucella spp., Leptospira spp., and to treat tuberculosis. Although 
most aminoglycosides used in human medicine are authorized for veterinary 
medicine with exceptions depending on the animal species, there are certain 
aminoglycosides, such as arbekacin, restricted to human medicine. On the other 
hand, one aminoglycoside especially relevant for veterinary medicine, apramycin, 
has not been lisenced for use in humans (Matt et al., 2013). Apramycin has been 
use extensively in veterinary medicine since the early 1980s. It is considered safe 
in most species although it is relatively toxic in cats. Apramycin is used for the 
treatment of colibacillosis and salmonellosis in calves, bacterial enteritis in pigs, 
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colibacillosis in lambs and E. coli septicemia in poultry. It is also administered to 
rabbits, but it is not authorised for use in laying birds or in cattle or sheep 
producing milk for human consumption. Due to its unique structure, apramycin 
remained safe from the action of aminoglycoside modifying enzymes for a long 
time. However, the appearance of the AAC(3)-IV enzyme, which acetylates not 
only apramycin, but other aminoglycosides including gentamicin and tobramycin, 
posed a great concern as these aminoglycosides are important in human medicine.    
 
1.4.2- Other applications of aminoglycosides  
 Despite the high number of aminoglycoside compounds that have been 
found in the last 60 years, only a few of them have been proven effective in human 
clinical practice as bactericidal agents, mainly those belonging to the 4,5 and 4,6-
disubstituted DOS groups and streptomycin. However, some of them can be useful 
for other purposes. For instance, two 5-monosusbstituted DOS, called destomycin 
A and hygromycin B, are used as anthelmintics in animals. Furthermore, some 
aminoglycosides, such as paromomycin, ribostamycin and streptomycin, have 
shown a significant antifungal and antioomycete activity (Lee et al., 2005). As 
these infections can be wide-host-range plant pathogens, these aminoglycosides 
were found to be a good weapon against significant plant diseases affecting many 
crops. A few aminoglycosides, such as geneticin (G-418), are available as 
biochemical reagents for molecular biology (Nudelman et al., 2010). This is due to 
the activity of certain aminoglycosides against the protein synthesis of eukaryotes, 
as the difference in binding specificity on the 70S ribosomes of prokaryotes or the 
80S ribosomes of eukaryotes comes from a conserved base difference in the 
16S/18S rRNA (A1408/G1408) (Eustice and Wilhem, 1984). Molecules with a 
hydroxyl function at C-6´ instead of an amino function, have been found to be 
more effective inhibitors of eukaryotic protein synthesis (Shalev et al., 2012). This 
has been exploited by several clinical studies that have been carried out over the 
last two decades to determine the potencial role of these aminoglycosides in the 
treatment of genetic diseases such as hemophilias and cystic fibrosis (James et al., 
2005). These genetic disorders are caused by nonsense mutations that lead to the 
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accumulation of truncated proteins. A few aminoglycosides including G-418, 
gentamicin, and paromomycin have been shown to suppress premature peptide-
chain termination and partially restore functional protein production in the case of 
more than 20 genetic diseases (Keeling and Bedwell, 2011). A temporary 
alleviation of the symptoms of these disorders after the administration of these 
aminoglycosides has been reported. However, ongoing studies are needed for 
further development. Nevertheless, the toxicity issues associated with these 
antibiotics still limit their clinical applications for this purpose.   
 
1.4.3- Discovery of new aminoglycosides  
 Since the most recently approved semi-synthetic aminoglycoside arbekacin 
in 1990, no new aminoglycoside antibiotics have been launched. The discovery of 
the first aminoglycoside resistance strains via modifying enzymes led to the first 
investigations of the 3-D atomic structure of these enzymes as well as to the 
development of inhibitors of aminoglycoside resistance enzymes. The prevention 
of these aminoglycoside modifications is attemped via various strategies (Boehr et 
al., 2005). One strategy involves the use of aminoglycosides where the functional 
group that is modified by a particular enzyme is missing, for example tobramycin 
and dibekacin lack the 3´hydroxyl group that is phosphorylated in kanamycin by an 
APH(3´). Another strategy consists of modifying aminoglycosides by disrupting 
interactions that are critical for the affinity between the antibiotic and a particular 
enzyme. Also the site of inactivation can be blocked, for example with a methyl 
group, as in the case of the kanamycin derivative 6´-N-methylkanamycin. 
However, this kind of approach is not broadly applicable since hundreds of 
different enzymes have appearedin the last decades, and one bacterium often 
carries multiple enzymes. Additionally, many of the structural requirements for the 
bactericidal activity of aminoglycosides are targeted by resistance enzymes.  
 Although the modifying enzymes constitute the most widely disseminated 
and frequent aminoglycoside resistance mechanism, the recent emergence of the 
16S rRNA methyltransferases as a high-level resistance determinant, the potential 
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value of certain aminoglycosides for the treatment of genetic diseases, and the 
toxicity issues related to the existing aminoglycosides, have led to an urgent 
necessity to find new aminoglycoside molecules. Over the last few years several 
synthetic derivatives of aminoglycosides, such as NB74 and NB84, were developed 
to overcome some of the toxicity issues (Nudelman et al., 2009). A recent 
medicinal chemistry campaign by the biopharmaceutical company Achaogen, 
yielded a collection of over 400 sisomicin analogs, and ACHN-490, later called 
plazomicin, was selected. ACHN-490 (plazomicin) is the only novel 
aminoglycoside derivative currently under clinical trial to combat MDR gram-
negative pathogens, and human studies to date have not reported nephrotoxicity or 
ototoxicity, as well as a lack of ototoxicity has been reported in a guinea pig model 
(Zhanel et al., 2012).  
 
1.5- Toxicity of aminoglycosides    
 As mentioned before, a major drawback to the use of aminoglycosides is 
their tendency to cause adverse effects. The side effects of this class of drugs that 
must be highlighted are the ototoxicity, nephrotoxicity, and in rare cases 
neurotoxicity (Jiang et al., 2006). Several factors influence the incidence of both 
the ototoxicity and nephrotoxicity, such as the choice of drug, duration of the 
treatment, or the functionality of the kidney. For instance, neomycin is more 
nephrotoxic and ototoxic than gentamicin or tobramycin. Longer therapies have 
been shown to cause a higher incidence of hearing loss, although isolated clinical 
cases where a single injection led to hearing loss have been reported (Forge and 
Schacht, 2000). This sensitivity was discovered to be associated to a mutation in 
the mitochondrial ribosomal RNA where a guanosine to adenosin substitution 
occurs at position 1555. Moreover, 17% of patients with an aminoglycoside-
induced hearing loss may be carriers of this mutation. Also the physiological state 
of the patient is crucial, so a decreased kidney function may increase the risk of 
developing side effects. Other factors such as the patient age or the co-
administration with other drugs have been suggested to play a role in the toxicity 
levels of aminoglycosides.    
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 The mechanisms involved in aminoglycoside toxicity have been a matter of 
discussion. However, there is experimental evidence for aminoglycoside-induced 
dysfunction of mitochondrial ribosomes as a cause for the toxicity. Impaired 
mitochondrial function results in the formation of reactive oxygen species (ROS), 
which may be directly involved in the toxic effects. The interaction of 
aminoglycosides with metal ions, which has been called 
“metalloaminoglycosides”, has been related to their activity and toxicity, as it 
enhances the formation of ROS (in metal-catalyzed oxidations) under physiological 
conditions. The metal-chelating abilities of aminoglycosides have been 
investigated in the context of cellular toxicity, and studies of iron complexes with 
neomycin and gentamicin have provided a molecular insight into ototoxicity 
pathways (Jiang et al., 2007). Despite the linkage between these metal complexes 
and toxicity, the enhanced biological activities of the metalloaminoglycosides 
suggest a potential therapeutic application that is currently being investigated. 
Thus, a therapeutic benefit would be obtained if an appropriate 
metalloaminoglycoside could damage the target molecules, while promoting a 
beneficial chemistry and minimizing the toxic side effects. The general symptoms 
observed after aminoglycoside-induced toxicity are summarized in Figure 3.    
            
 
Figure 3. General effects of aminoglycoside-induced toxicity.   
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1.5.1- Ototoxicity  
 This toxicity is considered the major disadvantage of aminoglycosides, as, 
in contrast to the renal effects, which can be reverted, the ear damages are 
irreversible, leading to permanent loss of hearing and balance. Ototoxicity has been 
associated with both natural and semisynthetic aminoglycosides (Edson and Terrel, 
1999). The ototoxicity is associated with the destruction of the sensory cells of the 
inner ear, which are essential for the transduction of auditory stimuli and the 
sensation of balance. Aminoglycosides enter the inner ear through the bloodstream 
rapidly after parenteral administration. The concentration of the drug reached in the 
inner ear does not necessarily correlate with the severity of damage, however its 
extreme persistence does, since despite their quick tissue penetration, 
aminoglycosides are not efficiently cleared. Thus, whereas the half-life of most 
aminoglycosides in the blood is around 3-5 hours, their half-life in the inner ear 
tissues may be up to 30 days. Ototoxic effects usually develop after the completion 
of the treatment. These effects include damage to the vestibular system, which 
results in balance disorders, and damage to the cochlea, resulting in hearing loss. 
Aminoglycosides can cause one or more of these effects, although the tissue targets 
can vary and this variation does not follow a structure-activity relationship. In other 
words, gentamicin is more vestibulotoxic than cochleotoxic in humans whereas 
amikacin or neomycin are more cochleotoxic. On the other hand, streptomycin is 
considered exclusively vestibulotoxic. Likewise, there is no correlation between 
the effects of certain aminoglycoside on the inner ear and on the kidney. 
Interestingly, the ototoxicity of gentamicin can be exploited to treat some 
individuals with Ménière’s disease by destroying the inner ear, which stops the 
vertigo attacks but causes permanent deafness.   
 
1.5.2- Nephrotoxicity 
 As a consequence of the aminoglycosides’ polar structure, they poorly cross 
membranes and thus the intracellular tissue concentration is low except in the 
proximal renal tubule where this concentration is high. Approximately, 5% of the 
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administered dose is retained in the epithelial cells lining the S1 and S2 segments 
of the proximal tubules after glomerular filtration. After several days of 
administering the clinical dose, signs of tubular dysfunctions may appear. In 
humans, these signs may be followed by an overt renal failure. However, a 
recovery after the termination of the treatment is often observed. In contrast, in 
animals, higher doses (i.e. 40mg/kg or more for gentamicin) are necessary to 
induce an overt renal dysfunction after the first symptoms (Mingeot-Leclercq and 
Tulkens, 1999). Once-a-day dosing is a successful strategy to avoid nephrotoxicity, 
although other protective approaches such as the co-administration of polyaspartic 
acid or deferroxamine have also been shown to diminish the nephrotoxic effects.  
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CHAPTER 2. Bacterial resistance to aminoglycosides 
 
 Despite the significant improvement of medicine when antibiotics became 
available for the treatment of bacterial infections, the situation drastically changed 
as soon as bacteria responded by manifesting resistance to those antibiotics. 
Nowadays, antibiotic resistance poses one of the major threats for Public Health, as 
it often results in treatment failure, which has serious consequences especially in 
critically ill patients (Tenover, 2006). Furthermore, the continuous and rapid 
emergence and spread of resistance mechanisms to all clinically available 
antibiotics compared to the lack of discovery of new bactericidal molecules in the 
last decades poses a great concern regarding the future of infection control. This 
situation has been aggravated due to the misuse of antibiotics, which is a 
contributing factor for the selection of resistant bacteria, and in the last years, 
several Governments and Public Institutions worldwide have raised awareness 
concerning the correct use of antibiotics through various campaigns (Huttner et al., 
2010) (Figure 4). This problem is not only related to nosocomial infections within 
healthcare institutions, but to community-acquired infections as well. Moreover, 
antibacterial drug resistance adds a burden to the healthcare systems (McGowan, 
2001).     
 Usually, susceptible bacteria may become resistant to antibiotics through 
mutation, or by acquiring the genetic information that encodes resistance from 
other bacteria (genetic exchange). The mechanisms of genetic exchange in bacteria 
include conjugation, transformation, and transduction, which accelerate the spread 
of resistance via horizontal gene transfer that may occur between strains from the 
same or different species or genera (McManus, 1997). This type of acquired 
resistance seriously contributes to the appearance of multidrug resistant bacteria 
that have become a cause of major concern, particularly in hospitals.  
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 Aminoglycosides were one of the first antibiotic classes identified during 
the “Golden Age” of antibiotic discovery (late 1940s-early 1960s), and they were 
seen a clinical revolution due to their broad-spectrum and excellent bactericidal 
activity against insidious gram-negative bacteria and mycobacteria (Falagas et al., 
2011). In line with other antibiotics, resistance to aminoglycosides has had a 
profound impact on the usefulness of these agents. The first reports of enzyme-
mediated aminoglycoside resistance by Umezawa and colleagues in the 1960s, 
spurred the search for new aminoglycosides. The natural compound tobramycin 
and the semisynthetic compound amikacin, introduced in the early 1970s, avoided 
the first emerged resistance mechanisms to gentamicin and kanamycin, but since 
then, only a few aminoglycosides were launched into clinic use, mostly in Japan. 
The most propitious of those were isepamicin and arbekacin. The general 
mechanisms of bacterial resistance to aminoglycosides are the reduction of the 
intracellular concentration of the antibiotic, the enzymatic modification of the drug, 
Figure 4. Campaigns that promote the rational use of antibiotics.  
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and the modification of the molecular target. These mechanisms will be extensively 
described in chapters 2 and 3.  
 
2.1- Decreased intracellular concentration 
    The reduced concentration of aminoglycosides inside the bacterial cell is 
due to an altered transport via import or export mechanisms. Thus, the lower 
antibiotic concentration is achieved either by a reduction of drug uptake or an 
expulsion of the drug by efflux systems.  
 
2.1.1- Reduced aminoglycoside uptake   
 Aminoglycoside entry to the cell has been shown to require a proton motive 
force generated by the respiratory chain. Therefore, anaerobic bacteria are 
intrinsically resistant to aminoglycosides due to the lack of drug uptake. In the 
same manner, mutants deficient in components of the electron transport chain, such 
as ATP synthases, show an altered aminoglycosides transport and are consequently 
resistant. This type of mutant has been isolated from endocardium infections 
caused by E. coli, P. aeruginosa, and S. aureus (Balwit et al., 1994). In P. 
aeruginosa it is more frequent than in other bacterial species to observed a reduced 
susceptibility to aminoglycosides due to a diminished uptake. Gentamicin 
resistance conferred by the inactivation of OprH, an outer-membrane porin protein, 
has been reported. The implication of the two-component regulatory system phoP-
phoQ on this resistance has also been shown, as these are the regulators of several 
genes involved in lipopolysaccharide modification (Bryan et al., 1984). When the 
lipopolysaccharide is less negatively charged, it exhibits a lower affinity for 
gentamicin. Furthermore, the alginate gel excreted by mucoid strains of P. 
aeruginosa, seems to play a role in the decreased aminoglycoside uptake, likely 
due an ionic trap for the antibiotic molecule (Hatch and Schiller, 1998).      
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2.1.2- Aminoglycoside efflux   
 Antibiotic efflux is an energy-dependent process that significantly 
contributes to multidrug resistance in a number of bacteria. In the last years, 
various efflux mechanisms whose 
genes are located on either plasmids 
or chromosomes have been 
described in a variety of organisms. 
Some of these mechanisms are 
agent- or class-specific while others 
are non-specific. There are five 
families of transmembrane efflux 
systems associated with antibiotic 
resistance (Table 3) (Poole, 2005). 
These are the major facilitator 
superfamily (MF), the ATP-binding 
cassette family (ABC), the 
resistance-nodulation division 
family (RND), the small multidrug 
resistance family (SMR), and the 
multidrug and toxic compound extrusion family (MATE). Usually, bacteria 
constitutively expressing these systems are intrinsically resistant to low levels of 
various antibiotics.  However, when there are mutations in the regulatory genes of 
the pumps, or an induction of the expression in the presence of the substrate, there 
is an overexpression of the pump genes that may lead to an increased resistance. 
The efflux system most relevant to gram-negative resistant bacteria is the 
resistance-nodulation division family (RND). The transporters of this family use 
the membrane proton motive force as an energy source. An RND system consists 
of three major components: the RND pump, a periplasmic membrane fusion 
protein (MFP), and an outer-membrane factor (OMF) (Figure 5).  In recent years, 
aminoglycosides have been shown to act as substrates for a number of multidrug 
efflux pumps belonging to the five families, although the majority of known 
aminoglycoside exporters belong to the RND family (Poole, 2005).  Nevertheless, 
Figure 5. A representative RND efflux system 
consisting of three main components: OMF (outer 
membrane factor), MFP (membrane fusion 
protein), RND (pump).    
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most RND pumps act more effectively against lipophilic and amphiphilic 
substrates, thus, the hydrophilic aminoglycoside molecules are poor substrates for 
these transporters. Aminoglycoside efflux is a significant mechanism of conferring 
aminoglycoside resistance in bacteria of the genera Pseudomonas, Burkholderia, 
and Stenotrophomonas, although efflux-mediated aminoglycoside resistance has 
also been described in other bacteria. The first aminoglycoside efflux system, 
AmrAB-OprA, was reported in Burkholderia pseudomalei. Since then, others have 
been reported in P. aeruginosa, E. coli, Lactococcus lactis, Acinetobacter 
baumanii, and Stenotrophomonas spp. (Table 3). The first pump found in P. 
aeruginosa was the MexAB-OprM system, although its ability to expel 
aminoglycosides is restricted to low-ionic-strength media (Masuda et al., 2000). 
The most effective efflux pump in P. aeruginosa is MexXY-OprM (Aires et al., 
1999). The genes mexXY are co-located in an operon with mexZ, which encodes for 
the negative regulator of mexXY. The expression of mexXY is inducible by 
aminoglycosides, so the exposure of the bacterium to any aminoglycoside leads to 
an enhanced pan-aminoglycoside resistance that is, however, quickly lost in the 
absence of the drug.  
Table 3. Families of efflux systems associated with antibiotic resistance, and main 
pumps involved in resistance to aminoglycosides.  
Family Efflux system Organism Location 
MF MdfA E. coli Plasmid 
ABC LmrA L. lactis Chromosome 
AmrAB-OprB B. pseudomallei Chromosome 
BpeAB-OprB B. pseudomallei Chromosome 
MexAB-OprM P. aeruginosa Chromosome 
MexXY-OprM P. aeruginosa Chromosome 
AcrAD-TolC E. coli Chromosome 
AdeAB-AdeC A. baumanii Chromosome 
RND 
SmeAB-SmeC S. maltophilia Chromosome 
SMR EmrE P. aeruginosa Chromosome 
MATE AbeM A. baumanii Chromosome 
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 In E. coli, AcrAD-TolC is the aminoglycoside resistance efflux-mediated 
system homologous to MexXY-OprM. There are several AcrD homologs in other 
members of the Enterobacteriaceae family, which suggests that this pan-
aminoglycoside resistance system may exist in other gram-negative bacteria. 
Although the efflux genes involved in aminoglycoside resistance are located in the 
bacterial chromosome, members of the major facilitator superfamily (MF) have 
also been shown to decrease aminoglycoside susceptibility in strains harbouring the 
structural gene on a multicopy plasmid.   
 
2.2- Enzymatic drug modification 
 The aminoglycoside modifying enzymes are the most prevalent mechanism 
of aminoglycoside resistance (Tolmasky, 2007). They are classified into three 
families: the aminoglycoside N-acetyltransferases (AACs), the aminoglycoside O-
nucleotidyltransferases (ANTs), and the aminoglycoside O-phosphotransferases 
(APHs). These enzymes modify their target aminoglycosides at −OH or −NH2 
groups by using either ATP or acetylCoA as co-substrates. The modified groups of 
the antibiotic are usually essential for aminoglycoside binding to the ribosome 
(Figure 6). Many of the genes encoding these enzymes are located on mobile 
genetic elements facilitating horizontal gene transfer. Nevertheless, some bacteria 
also bear these genes in the chromosome, for example, the Enterococcus faecium 
chromosome harbours a ubiquitous gene encoding for the AAC(6´)-Ii enzyme. Due 
to the high number of enzymes, their rapid spread, and their continuous evolution, 
this mechanism is widespread among all clinically important bacterial species 
(Shaw et al., 1993).  
 The large number of aminoglycoside modifying enzymes and their 
encoding genes has required a standardized nomenclature. However, there are still 
two main nomenclatures currently in use for these enzymes (Novick et al., 1976; 
Vanhoof et al., 1998). The oldest nomenclature system designates the genes as aac 
(for AACs), aad (for ANTs), and aph (for APHs) followed by a capital letter that 
identifies the modification site in the aminoglycoside (e.g. aacA stands for 
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aminoglycoside 6´-N- acetyltransferase). Subsequently a number that identifies a 
specific gene is added (i.e., aacA3). The other nomenclature system consists of 
AAC, ANT, or APH, referring to the family and related to the type of activity, 
followed by the modification site in parenthesis (class), a roman numeral referring 
to the resistance phenotype (subclass), and a lower case letter for the specific gene 
(i.e., AAC(6´)-Ia). Authors differentially prefer one system or the other, as both of 
them have advantages and disadvantages. But often, there is confusion or 
duplication when naming new variants, making it difficult to follow the updates in 
this field. For this reason it has already been suggested to use a single 
nomenclature system, which will facilitate the classification and study of these 
enzymes.   
 
 
2.2.1- Aminoglycoside N-acetyltransferases (AACs) 
 The AACs catalyze the acetyl-CoA-dependent N-acetylation of one of the 
four amino groups of the typical aminoglycosides. This acetylation reduces the 
affinity of these compounds for their target in the 30S ribosomal subunit. The 
acetylation occurs after the binding of acetyl-CoA and the amino group of the 
antibiotic takes place, and Levings and colleagues proposed a direct nucleophilic 
Figure 6. Modification of the 6´-NH2 of the 2-DOS which 
binds to the A1408 of the bacterial 16S rRNA.   
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attack by the amine on the thioester (Levings et al., 2005). Enzymes belonging to 
this family are present in both gram-positive and gram-negative bacteria, and they 
generally show a very broad aminoglycoside resistance profile.  
 The 3D structures of various acetyltransferases have been resolved, 
showing that they share similarity to one another, but they are also linked to the 
GCN5-related N-acetyltransferases (GNAT) superfamily (Azucena and Mobashery, 
2001). The GNAT family is characterized by low amino acid sequence similarity 
but share a common 3D structure. Thus, even though the amino acid sequences of 
the AACs are quite different from one another, they present similar 3D-folding 
patterns formed around the acetyl-CoA binding pocket.  The characteristic motifs 
that constitute the structure of these enzymes are: an N-terminal α-helix, a central 
antiparallel β-sheet, and a four-stranded mixed β-sheet flanked by two α-helices at 
the C-terminus (Figure 7).  
Figure 7. The 3D structure of some aminoglycoside modifying enzymes. A: 
AAC(3)-CoA complex; B: ANT(4´)-kanamycin A complex; C: Comparison of the 
APH(3´)-IIIa and residues 35-280 of the catalytic subunit of a eukaryotic protein 
kinase. A and B adapted from Magnet and Blanchard, 2005. C adapted from Burk et 
al., 2002.     
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 The GNAT enzymes are able to modify different acyl-accepting substrates, 
thus, AACs have been shown to modify not only aminoglycosides but other 
substrates (i.e., AAC(6´)-Ii acetylates certain GNAT substrates such as 
ribonuclease A or histones). Furthermore, aminoglycoside binding to the AACs 
may require the presence of water molecules. These indicators have led to the 
hypothesis that AACs may have other functions in the cell and could have evolved 
the ability to modify aminoglycosides (Houghton et al., 2010). This family of 
enzymes is continuously evolving, evidence of that being the discovery of the 
bifunctional AAC(6´)-Ib-cr a few years ago, which is a variant of AAC(6´)-Ib that 
is able to also modify fluoroquinolones (Vetting et al., 2008).  
 The AAC family are classified into four major classes based on their 
regiospecificity of acetyl transfer on the aminoglycoside structure: AAC(6´), 
AAC(2´), AAC(1), and AAC(3). The aminoglycoside N-acetyltransferases are 
listed in Table 4.    
 
2.2.1.1- AAC(6´) 
 As it is extensively known, the 6´-amino group of aminoglycosides plays an 
important role in their binding to the 30S ribosomal subunit and the subsequent 
antibacterial activity. Therefore, it is not surprising that this group is targetted by a 
major class of aminoglycoside-modifying enzymes, the AAC(6´) class (Ramirez 
and Tolmasky, 2010). These enzymes are the most common and they can be 
extensively found in both gram-positives and gram-negatives, on plasmids and 
chromosomes. There are two main subclasses of AAC(6´) enzymes depending on 
their resistance profiles, AAC(6´)-I and AAC(6´)-II. The subclass AAC(6´)-I 
exhibits resistance to gentamicin C1a and C2, and to amikacin, but not to 
gentamicin C1, whereas the AAC(6´)-II enzymes show resistance to the three 
gentamicins but not to amikacin. A derivative of AAC(6´)-Ib with two amino acids, 
AAC(6´)-Ib-cr, shows additional resistance to fluoroquinolones and it is considered 
a third subclass of AAC(6´) enzymes. These three subclasses were thought to be 
very related, however, Salipante and Hall have suggested that they are less related 
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and the 6´acetylating activity has evolved independently at least three times 
(Salipante and Hall, 2003).  Due to the large number of genes identified belonging 
to this class of enzymes, plus the absence of a unique nomenclature system, there 
have been several mistakes and difficulties when naming and classifying AAC(6´) 
enzymes. The existence of fusion proteins containing AAC(6´) activities has been 
reported, being the AAC(6´) protein located on the N or C terminal region of the 
composite protein. An AAC(6´) has been found fused to an APH, an ANT, 
AAC(6´), and to other AAC enzymes (Zhang et al., 2009). For instance, the 
AAC(6´)-APH(2´´) is a bifunctional enzyme found in Enterococcus faecalis and S. 
aureus, and the gene is usually found in Tn4001-like transposons (Culebras and 
Martinez, 1999).   
 One of the most clinically relevant acetyltransferases is AAC(6´)-Ib, 
isolated from Acinetobacter, Enterobacteriaceae, Pseudomonadaceae, and 
Vibrionaceae. Its gene is mainly found within class 1 integrons, although the 
genetic environment is particular. Instead of the normal attI recombination site 
adjacent to the intI gene upstream of the aac(6´)-Ib gene, there is an 8 bp sequence 
known as attI1* near the beginning of the gene (Centron and Roy, 2002). Many 
variants of this enzyme that differ in their N-terminal domains have been found, 
and this may be due to the high mobility of these genes (Casin et al., 1998). There 
is a high flexibility in the structural requirements of the protein N-terminal, as most 
of these variants are active, this may also contribute to the successful 
predominance of this protein among Enterobacteriaceae. Some of these variants 
show an extended spectrum. For instance, variant AAC(6´)-Ib11 confers resistance 
to all three gentamicins, and AAC(6´)-Ib-cr leads to a reduced susceptibility to 
quinolones, and it has been frequently found in different integrons associated with 
quinolone resistance genes such as qnr or qepA, and β-lactamase genes.      
 
2.2.1.2- AAC(1) 
 This class of acetyltransferase is not very frequent compared to the 
AAC(6´) enzymes, and its importance is minor because they do not modify the 
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most clinically relevant aminoglycosides. They have been found in actinomycete, 
E. coli, and Campylobacter spp. (Lovering et al., 1987; Sunada et al., 1999). The 
substrate profile of AAC(1) enzymes consists of neomycin, ribostamycin, 
apramycin, butirosin, paromomycin and lividomycin. Whereas the substrate profile 
of the AAC(1) isolated from E. coli and Campylobacter spp. is similar, the AAC(1) 
isolated  from an actinomycete is not able not acetylate apramycin.  
 
2.2.1.3- AAC(2´) 
 There are five aminoglycoside acetyltransferases that catalyze the 
acetylation of the 2´- amino group, and only one subclass exists. AAC(2´)-Ia was 
the first one identified from Providencia stuartii, while AAC(2´)-Ib, AAC(2´)-Ic, 
AAC(2´)-Id, and AAC(2´)-Ie have been identified in different Mycobacterium spp. 
(Ainsa et al., 1997; Hegde et al., 2001; Rather et al., 1993). AAC(2´)-Ib has also 
been isolated from A. baumanii. These five enzymes are chromosomally encoded 
and are generally species specific, they are also considered to be universally 
present in mycobacteria. These modify various aminoglycosides including 
gentamicin, kanamycin, tobramycin, netilmicin, and dibekacin. Regarding 
AAC(2´)-Ia, a low level of expression of the gene that is not able to confer 
aminoglycoside resistance has been reported in wild-type bacteria, however, this 
gene’s regulation is complex. Some studies have shown that a mutation in the 
aac(2´)-Ia gene leads to differences in cell morphology due to altered levels of 
peptidoglycan O-acetylation, thus, this may be a physiologic function of the 
AAC(2´)-Ia enzyme.  
 The three-dimensional structure of the AAC(2´)-Ic has been reported, 
confirming that it belongs to the Gcn5-related N-acetyltransferase (GNAT) 
superfamily. The activity of this enzyme is highest with aminoglycosides 
containing a 2´-amino group, however, in contrast with other acetyltransferases, 
AAC(2´)-Ic is active against kanamycin A and amikacin, which contain a 2´-
hidroxyl group. Therefore, this enzyme may catalyze O-acetylation.   
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2.2.1.4- AAC(3)  
 This family is one of the largest and includes nine subclasses described to 
date based on the pattern of aminoglycoside resistance that they confer (Shaw et 
al., 1993). The subclasses are named AAC(3)-I to AAC(3)-X except subclass 
AAC(3)-V, which was eliminated when it was shown that the only enzyme 
belonging to this group was the previously described AAC(3)-II.  
 Five enzymes have been identified within the subclass AAC(3)-I (a-e) 
widely distributed among gram-negative bacteria and they are characterized by 
conferring resistance to fortimicin, sisomicin and gentamicin. The AAC(3)-Ia 
originally identified in 1991 from Serratia marcescens was the first 
aminoglycoside acetyltransferase whose three-dimensional structure complexed to 
CoA was determined showing that the monomer fold was typical of the GNAT 
superfamily. The genes encoding these five enzymes have been found within 
integron cassettes.     
 The subclass AAC(3)-II includes three enzymes, and they confer resistance 
to gentamicin, tobramycin, sisomicin, netilmicin, and dibekacin. AAC(3)-IIa has 
been found widely distributed among different genera, while AAC(3)-IIb has only 
been identified in E. coli, Alcaligenes faecalis and S. marcescens, and AAC(3)-IIc 
in P. aeruginosa and E. coli.  
 As with the subclass AAC(3)-II, the subclass AAC(3)-III is comprised of 
three enzymes, all of them have been isolated from P. aeruginosa. When the 
aac(3)-IIIa gene was firstly cloned, it was expressed in P. aeruginosa but not in E. 
coli, which was explained by the authors as the incomplete synthesis of the mRNA 
or an obstruction of the initiation of translation (Vliegenthart et al., 1991).  
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Table 4. Aminoglycoside N-acetyltransferases 
AAC Gene names Host Genetic location 
AAC(1) aac(1) E. coli, Actinomycetales, Campylobacter spp. ND 
AAC(3)-Ia* aac(3)-Ia, aacC1 
S. marcescens, E. coli, A. 
baumanii, K. pneumoniae, K. 
oxytoca, P. aeruginosa, S. 
typhimurium, P. mirabilis 
Plasmid, 
transposon, 
integron 
AAC(3)-Ib aac(3)-Ib P. aeruginosa Integron 
AAC(3)-Ic aac(3)-Ic P. aeruginosa Integron 
AAC(3)-Id aac(3)-Id S. enterica, P. mirabilis, Vibrio fluvialis 
Genomic island, 
integron 
AAC(3)-Ie aac(3)-Ie, aacCA5 
S. enterica, P. mirabilis, P. 
aeruginosa Integron 
AAC(3)-IIa 
aac(3)-IIa, 
aacC3, aacC5, 
aacC2, aac(3)-
Va 
K. pneumoniae, E. cloacae, 
Actinobacillus 
pleuropneumoniae, S. 
Typhimurium, C. freundii   
Plasmid 
AAC(3)-IIb aac(3)-IIb, aac(3)-Vb 
E. coli, E. faecalis, S. 
marcescens ND 
AAC(3)-IIc aac(3)-IIc, aacC2 E. coli, P. aeruginosa Plasmid 
AAC(3)-IIIa aac(3)-IIIa, aacC3 P. aeruginosa Chromosome 
AAC(3)-IIIb aac(3)-IIIb P. aeruginosa ND 
AAC(3)-IIIc aac(3)-IIIc P. aeruginosa ND 
AAC(3)-IVa aac(3)-IVa E. coli, C. jejuni, P. stutzeri Plasmid 
AAC(3)-VIa aac(3)-VIa E. cloacae, S. enterica, E. coli Plasmid 
AAC(3)-VIIa aac(3)-VIIa, aacC7 Streptomyces rimosus Chromosome 
AAC(3)-VIIIa aac(3)-VIIIa, aacC8 Streptomyces fradiae Chromosome 
AAC(3)-IXa aac(3)-IXa, aacC9 Micromonospora chalcea Chromosome 
AAC(3)-X aac(3)-Xa Streptomyces griseus Chromosome 
AAC(2´)-Ia aac(2´)-Ia P. stuartii Chromosome 
AAC(2´)-Ib aac(2´)-Ib M. fortuitum, A. baumanii Chromosome 
AAC(2´)-Ic* aac(2´)-Ic M. tuberculosis, M. bovis Chromosome 
AAC(2´)-Id aac(2´)-Id M. smegmatis Chromosome 
AAC(2´)-Ie aac(2´)-Ie M. leprae Chromosome 
AAC(6´)-Ia aac(6´)-Ia, aacA1 
Citrobacter diversus, E. coli, K. 
pneumoniae, Shigella sonnei 
Plasmid, 
transposon, 
integron 
AAC(6´)-Ib* 
aac(6´)-Ib, 
aac(6´)-4, 
aacA4 
K. pneumoniae, P. mirabilis, P. 
aeruginosa, S. enterica, K. 
oxytoca, S. maltophilia, E. 
cloacae 
Plasmid, 
transposon, 
integron 
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AAC(6´)-Ib’ aac(6´)-Ib’, aac(6´)-Ib6 
P. fluorescens, P. aeruginosa Integron 
AAC(6´)-Ic aac(6´)-Ic S. marcescens Chromosome  
AAC(6´)-Ie 
aac(6´)-Ie, 
aac(6´)-
bifuncional 
S. aureus, Macrococcus 
caseolyticus, E. faecalis, E. 
faecium 
Transposon 
AAC(6´)-If aac(6´)-If E. cloacae Plasmid 
AAC(6´)-Ig aac(6´)-Ig Acinetobacter haemolyticus Chromosome 
AAC(6´)-Ih aac(6´)-Ih A. baumanii Plasmid 
AAC(6´)-Ii* aac(6´)-Ii Enterococcus spp. Chromosome 
AAC(6´)-Ij aac(6´)-Ij Acinetobacter genomosp. 13 Chromosome 
AAC(6´)-Ik aac(6´)-Ik Acinetobacter spp. Chromosome 
AAC(6´)-Ip 
aac(6´)-Ip, 
aac(6´)-Il, 
aac(6´)-Im 
C. freundii Integron 
AAC(6´)-Iq aac(6´)-Iq K. pneumoniae Plasmid, integron 
AAC(6´)-Im aac(6´)-Im E. coli, E. faecium Plasmid 
AAC(6´)-Il aac(6´)-Il, aacA7 Enterobacter aerogenes Plasmid, integron 
AAC(6´)-Ir aac(6´)-Ir A. genomosp. 14 Chromosome 
AAC(6´)-Is aac(6´)-Is A. genomosp. 15 Chromosome 
AAC(6´)-Isa aac(6´)-Isa Streptomyces albulus Plasmid 
AAC(6´)-It aac(6´)-It A. genomosp. 16 Chromosome 
AAC(6´)-Iu aac(6´)-Iu A. genomosp. 17 Chromosome 
AAC(6´)-Iv aac(6´)-Iv Acinetobacter sp.  Chromosome 
AAC(6´)-Iw aac(6´)-Iw Acinetobacter sp. Chromosome 
AAC(6´)-Ix aac(6´)-Ix Acinetobacter sp. Chromosome 
AAC(6´)-Iy* aac(6´)-Iy S. enteritidis, S. enterica Chromosome 
AAC(6´)-Iz aac(6´)-Iz S. maltophilia Chromosome 
AAC(6´)-Iaa aac(6´)-Iaa S. Typhimurium Chromosome 
AAC(6´)-Iad aac(6´)-Iad A. genomosp. 3 Plasmid 
AAC(6´)-Iae aac(6´)-Iae P. aeruginosa, S. enterica Ingegron 
AAC(6´)-Iaf aac(6´)-Iaf P. aeruginosa Plasmid, integron 
AAC(6´)-Iai aac(6´)-Iai P. aeruginosa Plasmid, integron 
AAC(6´)-Ib3 
aac(6´)-Ib3, 
aac(6´)-Ib5 
P. aeruginosa Integron 
AAC(6´)-Ib4 aac(6´)-Ib4 Serratia spp.  ND 
AAC(6´)-Ib7 aac(6´)-Ib7 E. cloacae, C. freundii Plasmid 
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AAC(6´)-Ib8 aac(6´)-Ib8 E. cloacae Plasmid 
AAC(6´)-Ib9 aac(6´)-Ib9 P. aeruginosa Integron 
AAC(6´)-Ib10 aac(6´)-Ib10 P. aeruginosa ND 
AAC(6´)-Ib11* aac(6´)-Ib11 S. enterica Integron 
AAC(6´)-29a aac(6´)-29a P. aeruginosa Integron 
AAC(6´)-29b aac(6´)-29b P. aeruginosa Integron 
AAC(6´)-31 aac(6´)-31 Pseudomonas putida, A. baumannii, K. pneumoniae Integron 
AAC(6´)-32 aac(6´)-32 P. aeruginosa Plasmid, integron 
AAC(6´)-33 aac(6´)-33 P. aeruginosa Integron 
AAC(6´)-I30 aac(6´)-I30 S. enterica Integron 
AAC(6´)-Iid aac(6´)-Iid Enterococcus durans Chromosome 
AAC(6´)-Iih aac(6´)-Iih Enterococcus hirae Chromosome 
AAC(6´)-Ib-Suzhou aac(6´)-Ib-Suzhou E. cloacae, K. pneumoniae ND 
AAC(6´)-Ib-
Hangzhou 
aac(6´)-Ib-
Hangzhou A. baumannii ND 
AAC(6´)-SK aac(6´)-sk Streptomyces kanamyceticus Chromosome 
AAC(6´)-IIa aac(6´)-IIa P. aeruginosa, S. enterica Plasmid, integron 
AAC(6´)-IIb aac(6´)-Iib P. fluorescens Integron 
AAC(6´)-IIc  aac(6´)-IIc E. cloacae Plasmid, integron 
AAC(6´)-Ib-cr aac(6´)-Ib-cr Enterobacteriaceae 
Plasmid, 
transposon, 
integron 
AAC(6´)-Ie-
APH(2”)-Ia 
aac(6´)-Ie-
aph(2”)-Ia 
S. aureus, E. faecalis, E. 
faecium, Staphylococcus 
warneri 
Plasmid, 
transposon 
ANT(3”)-Ii-
AAC(6´)-IId 
ant(3”)-Ii-
aac(6´)-IId, 
ant(3”)-Ih-
aac(6´)-IId 
S. marcescens Integron 
AAC(6´)-
30/AAC(6´)-Ib’  
aac(6´)-
30/aac(6´)-Ib’ P. aeruginosa Integron 
AAC(3)-Ib/AAC(6´)-
Ib” 
aac(3)-
Ib/aac(6´)-Ib” P. aeruginosa Integron 
* Those enzymes for which the three dimensional structure has been resolved. Adapted from 
Ramirez and Tolmasky, 2010.  
 
 Within the subclasses IV and VI, a sole enzyme has been described. 
AAC(3)-IVa has been identified in clinical E. coli and Campylobacter jejuni, as 
well as environmental Pseudomonas stutzeri. In the case of AAC(3)-VIa, when the 
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original amino acid sequence from Enterobacter cloacae is compared to those later 
identified in E. coli and S. enterica, it shows one amino acid change.  
 Finally, the subclasses VII, VIII, IX, and X, have been identified among 
different strains of actinomycetes. Interestingly, AAC(3)-X is the only described 
AAC with AAC(3”) activity, as it is able to acetylate not only the 3-amino group of 
kanamycin and dibekacin but the 3”-amino group of amikacin and arbekacin (Hotta 
et al., 1998). However, the latter remains active after this modification.   
 
2.2.2- Aminoglycoside O-phosphotransferases (APHs) 
 These enzymes catalyze the ATP-dependent phosphorylation of key 
hydroxyl substituents present on the aminoglycoside molecule. They are widely 
distributed among bacterial pathogens and are encoded by genes usually found on 
multidrug resistance plasmids and transposons.  
 
 
  
 
 
 
 
 
 
 
 
Table 5. List of the existing APHs, and the classes and 
subclasses that they belong to.  
Class Subclass Members* 
APH(4) I Ia (hph), Ib (hyg) 
APH(6) I 
Ia (aphD, strA), Ib 
(sph), Ic, Id (strB, 
orfI) 
APH(9) I Ia, Ib (spcN) 
APH(3´) I, II, III, IV, V, VI, VII  
Ia (aphA-1), Ib 
(aphA), Ic (aphA7, 
aphA1-Iab), IIa 
(aphA-2), IIb, IIc, 
IIIa, IVa, Va, Vb, 
Vc, VIa (aphA-6), 
VIb, VIIa (aphA-7) 
APH(2”) I, II, III, IV Ia, Ie, IIa (Ib), IIIa (Ic), IVa (Id)  
APH(3”) I Ia (aphE, aphD2), Ib, Ic 
APH(7”) I Ia 
* Words in parentheses indicate an alternative name of the gene.  
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 This family includes a large number of enzymes, although they are more 
clinically relevant in gram-positive bacteria (Vakulenko and Mobashery, 2003). 
The classes and subclasses within the APHs are listed in Table 4, but only the 
APH(3´) enzymes are described in detail as they belong to the most extensive and 
best-studied class of APHs.     
 
2.2.2.1- APH(3´) 
 This family is especially ubiquitous and it has been widely used asa  
resistance marker in molecular biology research. The APH(3´)-I subclass is found 
within wide host range plasmids and transposons in gram-negatives (Tenover et al., 
1989), and there are three enzymes belonging to this subclass that confer resistance 
to neomycin, paromomycin, lividomycin, ribostamycin, and kanamycin. The 
aph(3´)-Ia and aph(3´)-Ic genes are commonly used as marker genes in cloning 
vectors. The aph(3´)-Ib gene is part of the broad host range conjugative RP4 
plasmid. The APH(3´)-II subclass includes the enzymes IIa, whose gene is also 
used in cloning vectors for prokaryotes and eukaryotes, IIb, encoded by a gene 
identified in the P. aeruginosa chromosome, and IIc, found in S. maltophilia.   
 The best-studied member of the APHs is the APH(3´)-IIIa, generally found 
in gram-positive pathogens. It confers resistance to a broad range of 
aminoglycosides including neomycin, lividomycin, paromomycin, butirosin, 
livostamycin, isepamicin, kanaycin, and amikacin. It does not modify tobramycin 
or gentamicin as both of them lack a free 3´-hydroxyl group. Nevertheless, it can 
phosphorylate other aminoglycosides that lack a 3´-hydroxyl group, such as 
lividomycin at position 5”. In addition, APH(3´)-IIIa is able to di-phosphorylate 
butirosin and neomycin B at both the 3´- and 5”- positions (McKay et al., 1994). 
This enzyme has been crystallized and the 3D structure has been determined, 
revealing a close similarity to kinases from eukaryotes, therefore, the APHs are 
known also as “aminoglycoside kinases” (Hon et al., 1997). They share almost a 
40% structural identity although the share less than 5% amino acid sequence 
homology. Like the eukaryotic kinases, the 3D structure consists of two domains: 
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an N-terminal β-sheet region responsible for ATP binding, and an α-helix at the C-
terminal, which acts as the aminoglycoside recognition site. The phosphate transfer 
occurs at the interface of the two domains, and it was suggested that the enzyme 
active site has evolved to “mimic” the rRNA binding site to facilitate the drug 
binding into this pocket before it can find its true target. Kinetic analyses have 
shown that this enzyme, like other kinases, requires divalent cations for its activity. 
Furthermore, it has been demonstrated that APH(3´)-IIIa is capable of 
phosphorylating several basic peptides, including protamine and myelin basic 
protein, although this activity is weak. Moreover, APHs can be inhibited by certain 
molecules that are known to inhibit kinases such as wortmannin, thus, it has been 
suggested that APHs evolved from protein or inositide kinases, maybe in an 
aminoglycoside producer where those proteins are well known.  
 Regarding the rest of APH(3´) enzymes, the aph(3´)-IVa gene is present in 
Bacillus circulans chromosome, whereas the aph(3´)-Va, aph(3´)-Vb, and aph(3´)-
Vc genes are located in the actinomycetes chromosome. The resistance profile for 
the subclass V includes neomycin, ribostamycin and paromomycin, and the 
enzymes belonging to subclass VI confer resistance to neomycin, paromomycin, 
ribostamycin, butirosin, kanamycin, amikacin, and isepamicin. The only member 
of subclass VII, APH(3´)-VIIa, confers resistance to kanamycin and neomycin, and 
it was identified in Campylobacter jejuni.   
 
2.2.3- Aminoglycoside O-nucleotidyltransferases (ANTs) 
 The ANTs represent the smallest class of aminoglycoside inactivating 
enzymes. These enzymes catalyze the reaction between Mg-ATP and 
aminoglycosides to form the O-adenylylated antibiotic molecule. To date, there are 
five classes of ANTs categorized depending on the position of adenylylation on the 
aminoglycoside molecule (Ramirez and Tolmasky, 2010): ANT(6), ANT(9), 
ANT(3”), ANT(2”), and ANT(4). Only one subclass exists within all of them 
except for ANT(4´), which includes two subclasses. The ANT(2”) and ANT(3”) 
enzymes are more frequent among gram-negative bacteria whereas the ANT(4´), 
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ANT(6), and ANT(9) are most usually found in gram-positive pathogens (Shaw et 
al., 1993). The genes coding for all of these enzymes are often identified on mobile 
genetic elements. The most commonly found ANTs are the ANT(3”) enzymes. 
However, they are not considered the most clinically relevant ANTs as they are 
characterized by specifically conferring resistance to only streptomycin and 
spectinomycin (Hollingshead and Vapnek, 1985).   
 One of the most clinically significant members of this family of enzymes is 
the ANT(2”)-Ia, as it is a highly prevalent cause of gentamicin resistance in North 
America, being widespread among gram-negative pathogens. Its gene (also 
commonly called aadB) has been found amongst diverse genetic backgrounds, 
such as small non-conjugative plasmids, conjugative plasmids, class 1 and 2 
integrons, or transposons (Ramirez et al., 2005). It confers resistance to 
gentamicin, kanamycin, tobramycin, sisomicin, and dibekacin.   
 The ANT(4´)-Ia, typically found in plasmids of Staphylococci and 
Enterococci, is the only ANT for which the 3-D structure has been reported 
(Pedersen et al., 1995). It revealed that this enzyme functions as a dimer, with the 
active site at the interface of both subunits (Figure 7). One subunit contributes to 
the binding of ATP and Mg2+, and the other subunit is required for the transfer of 
the adenyl moiety to the aminoglycoside targetted. The ANT(4´)-Ia, also named 
aadD, aadD2, and ant(4´,4”)-I, confers resistance to amikacin, tobramycin, and 
isepamicin, but also to dibekacin, which lacks a 4´- target and it is adenylated at 
position 4” by this enzyme. 
 The correlation between the modification site of certain enzymes and the 
aminoglycoside resistance profiles is shown in Figure 8.  
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2.3- Target modification 
 
2.3.1- Ribosomal mutations 
 Aminoglycoside resistance due to ribosomal mutations can occur either due 
to mutations of the ribosomal target (16S rRNA), or due to the mutation of 
ribosomal proteins (Magnet and Blanchard, 2005). Resistance to streptomycin by 
mutation of the ribosomal target in M. tuberculosis is the only case where this 
resistance mechanism is clinically relevant. Mycobacterium is the only genus of 
eubacteria with species that contain a single copy of the ribosomal operon, thus, a 
Figure 8. Modification site on the aminoglycoside molecule of selected enzymes and the 
resulting resistance profiles. A, amikacin; Dbk, dibekacin; G, gentamicin; Gmb, 
gentamicin B; I, isepamicin; K, kanamycin; N, netilmicin; S, sisomicin; T, tobramycin. 
Jana and Deb, 2006.  
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single mutation leads to the production of a population of mutant ribosomes 
resulting in resistance. rrs is the gene that encodes the 16S rRNA, and mutations in 
this gene affect two highly conserved regions, the 530 loop, and the region around 
nucleotide 912 (E. coli numbering), giving rise to streptomycin resistance in M. 
tuberculosis (Dobner et al., 1997). Apart from streptomycin resistance in M. 
tuberculosis, 16S rRNA mutations associated with aminoglycoside resistance have 
been described in clinical isolates of bacteria containing a single or low copy 
number of rrs genes. For instance, mutations at positions 1400 and 1401 have been 
reported in kanamycin-resistant M. tuberculosis, the mutation A1408G has been 
described in the rRNA operon of only M. abscessus and M. chelonae to be 
responsible for resistance to 2-DOS-containing aminoglycosides, and those 
mutations affecting the base pair G1064-C1192 of helix 34  have been shown to 
confer spectinomycin resistance in Neisseria.   
 There have been many studies using the introduction of a single rrs gene on 
a multicopy plasmid to test the effect of 16S rRNA mutants on the activity of 
aminoglycosides. These studies have shown that at least half of the ribosomes must 
be in the mutant form to confer aminoglycoside resistance (Meier et al., 1994). 
Other works have shown how mutations leading to an allosteric change in the drug-
binding pocket can be more counterproductive for aminoglycoside activity than 
those mutations avoiding direct contacts between the drug and the 16S rRNA.  
 Mutations in genes encoding ribosomal proteins can also modify the 
activity of aminoglycosides. Mutations in protein S12 are a cause of streptomycin 
resistance in M. tuberculosis and other species (Meier et al., 1994). Although 
structural data showed that S12 makes direct contact with streptomycin, it has been 
proven that the effect of such mutations is related to conformational changes in the 
rRNA that prevent drug binding. Apart from mutations in the 30S ribosomal 
subunit, certain mutations in components of the 50S have also been associated with 
resistance to various aminoglycosides. For instance, mutations in the N-terminal 
half of S5, which contact helix 34, can confer resistance to spectinomycin as they 
destabilize the network of interactions in the 30S subunit.     
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2.3.2- Methylation of the 16S rRNA  
 Nowadays this strategy constitutes the most worrisome resistance 
mechanism to the aminoglycoside antibiotics. For this reason, as well as for 
composing the main topic of this Thesis, it will be extensively described in the next 
Chapter.    
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CHAPTER 3. The 16S rRNA methyltransferases: an 
aminoglycoside high-level resistance mechanism.   
 
 Despite the continuous usefulness of aminoglycoside antibiotics since their 
discovery in 1944, the never-ending decrease of the development of new molecules 
combined with the increasing emergence of resistant strains has turned the 
resistance against this family of antibiotics into the central topic of numerous 
research works. 
 Until now, we have mentioned several types of aminoglycoside resistance 
mechanisms, of which the inactivation of the antibiotic molecule mediated by 
enzymes is the most common. Even so, those mechanisms do not confer high-level 
resistance as they usually depend on various factors such as the amount of drug-
inactivating enzyme produced. Moreover, they generally only have a few specific 
substrates so a coexistence of several complementary determinants is needed for a 
broader spectrum of activity. Regarding this point, when resistance is due to target 
modification, high levels of resistance to aminoglycosides can be achieved. As 
described before, modification of the target due to a ribosomal mutation rarely 
occurs and is only clinically significant in M. tuberculosis. However, there is a 
target-site modification in which the bacterium protects the target by employing 
enzymes that add a methyl group to specific nucleotides in the 16S rRNA that are 
essential for aminoglycoside binding, thus, inhibiting the antibiotic action without 
interfering with other ribosomal functions. This mechanism has become a major 
concern regarding aminoglycoside resistance, not only because high levels of 
resistance to most clinically relevant aminoglycosides can be achieved, but due to 
the potential of both the vertical and horizontal transfer of the genes encoding these 
enzymes. 
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3.1- Housekeeping 16S rRNA methyltransferases in aminoglycoside producers 
 Most antibiotics used in clinical settings are microbial secondary 
matabolites, and although there are various antibiotic-producing prokaryotes, the 
most prolific are the actinomycetes. Hence, antibiotic-producing organisms must 
be able to protect themselves against the toxic effects of their own products. This 
self-defence can be accomplished in different ways, from target-based protection to 
efflux systems or any other strategy that prevents the drug-target interaction 
(Cundliffe and Demain, 2010).  
 Self-defence involving the antibiotic target sites is widespread and it 
commonly involves ribosomes as most drugs that inhibit protein synthesis bind to 
specific sites located on any of the ribosomal subunits. These sites are principally 
comprised of rRNA, thus, self-resistance via site-specific methylation of rRNA is a 
widespread tactic used by those microorganisms producing agents that act on the 
ribosome (Savic et al., 2009). This does not only include aminoglycosides, but also 
other compounds such as macrolides, lincosaminides, or thiopeptides. However, 
ribosome-based resistance has not been found in all organisms that produce 
ribosome inhibitors, as is the case with producers of streptomycin, neomycin, 
tetracycline, or chloramphenicol (Cundliffe and Demain, 2010). The high-level 
resistance achieved by this ribosomal modification is generally produced by the 
action of a single rRNA methyltransferase that acts at a specific site characteristic 
of a given phenotype, even when it is a complex pattern. One example is the 
“MLS” phenotype (causing resistance to macrolides, lincomycin, and 
streptogramins), which is widespread among actinomycetes. Nevertheless, there are 
exceptions where rRNA methyltransferases act together, conferring resistance for 
example to tylosin in Streptomyces fradiae, or to avilamycin in Streptomyces 
viridochromogenes (Cundliffe and Demain, 2010).  
 Ribosomal modifications resulting in aminoglycoside self-resistance 
involve monomethylation of the 16S rRNA at one of two sites: G1405 or A1408 
(E. coli numbering). A substitution occurs on the nitrogen ring to generate 7-
methylguanosine or 1-methyladenosine, respectively, blocking the binding of 
certain aminoglycosides to the ribosome (Savic et al., 2009).        
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                Several MTs conferring aminoglycoside resistance in their producers 
have been described so far, mainly from different species of the genus 
Streptomyces, Micromonospora, and to a lesser extent, Saccharopolyspora (Table 
6) (Demydchuk et al., 1998; Kojic et al., 1992; Ohta et al., 1993). These MTs are 
included in the S-adenosyl-L-methionine (SAM)-dependent RNA enzyme 
superfamily and they have been classified in two groups of enzymes named the 
Kgm and Kam families (Conn et al., 2009). This classification is based on their 
target residue by ascertaining the site of methylation on the 16S rRNA by Matrix-
assisted laser desorption/ionization mass spectrometry (MALDI-MS). The Kgm 
(kanamycin-gentamicin MTs) family methylate residue G1405 whereas the Kam 
(kanamycin-apramycin MTs) family methylate the A1408 residue (Husain et al., 
2010; Macmaster et al., 2010; Savic et al., 2009). Comparison of antibiotic 
resistance patterns between both families unambiguously identifies functional 
differences correlating with the modifications at G1405 and A1408. All Kgm 
family members confer high-level resistance to 4,6-DOS aminoglycosides (such as 
kanamycin and gentamicin), with MIC values over 1000 mg/L. However, they do 
not reduce susceptibility to 4,5-DOS (neomycin, paromomycin) nor to other 
aminoglycosides such as apramycin and streptomycin. On the other hand, the Kam 
MTs do not confer resistance to gentamicin but they increase resistance levels to 
neomycin as well as they confer high-level resistance to kanamycin and apramycin.  
 
 
  
 
 
 
 
Table 6. Self-aminoglycoside resistance via methylation of 16S rRNA  
Aminoglycoside Producer Gene MT family 
Gentamicin M. purpurea gmrA 
Kanamycin S. kanamyceticus Kmr 
Nebramycin complex S. tenebrarius kgmB 
Fortimicin A M. olivasterospora fmrO 
Kgm 
(methylate G1405) 
Istamycin S. tenjimariensis kamA 
Nebramycin complex S. tenebrarius kamB 
Sporaricin Sac. hirsuta kamC 
Kam 
(methylate A1408) 
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 Genes of the Kgm and Kam families are typically present in respective 
antibiotic-biosynthesis clusters. Hence, grmA, kmr, and kamA are found within the 
gentamicin, kanamycin and istamycin biosynthesis clusters of M. purpurea, S. 
kanamyceticus, and S. tenjimariensis, respectively (Table 6). However, S. 
tenebrarius bears kgmB and kamB genes, belonging to the MT families Kgm and 
Kam, respectively. This is explained because S. tenebrarius is a producer of the so 
called “nebramycin complex”, which includes different aminoglycosides 
(apramycin and kanamycin B derivatives including tobramycin). The phylogenetic 
relationship between some of the MTs responsible for self-resistance in 
aminoglycoside producers is shown in Figure 9.            
 
                  
 
 
 
 
 
Figure 9. A dendrogram with relevant intrinsic 16S rRNA MTs from AG 
producers. A clear differentiation can be observed between the Kgm (blue) 
and the Kam (red) family members. The bar denotes genetic distance. 
Bootstrap values are the result of 1000 iterations.  
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3.2- Acquired 16S rRNA methyltransferases in gram-negative bacteria   
 It is known that large amounts of aminoglycosides have been used in the 
last decades for the treatment of infections caused by mainly gram-negative but 
also gram-positive bacteria. On the other hand, during this period of time, these 
bacteria have acquired several resistance mechanisms to inhibit aminoglycosides 
action. Among these mechanisms, as described above, the most frequently found 
was the enzymatic modification of the aminoglycoside molecule. Despite 
ribosomal protection via methylation being widely described as a self-defence 
strategy in aminoglycoside-producers since the 80’s, until recently, this resistance 
mechanism was believed to be absent in clinically relevant bacteria. Nowadays, the 
methylation of the ribosomal target responsible for high-level aminoglycoside 
resistance is an emerging mechanism of great concern in clinically relevant gram-
negative bacteria.      
 
3.2.1- General traits of acquired 16S rRNA MTs 
 
3.2.1.1- First description and nomenclature 
 In 2003, an acquired 16S rRNA MT was initially reported (Galimand et al., 
2003). A Klebsiella pneumoniae isolated in 2000 from a urinary tract infection in 
France was found to be highly resistant to all 4,6-DOS aminoglycosides and 
fortimicin. The genetic determinant responsible for that phenotype was cloned into 
a laboratory E. coli strain. The inserted sequence was compared with sequences in 
the GenBank data library, revealing sequence identity with a fragment of a plasmid 
sequence from Citrobacter freundii in Poland (pCTX-M3), which had been 
deposited in GenBank in 2002 under the accession number AF550415. There was 
an ORF within that fragment of which the deduced aminoacid sequence shared 
similarity (27%) with a 16S rRNA methyltransferase from Streptoalloteichus 
hindustanus. However, even though the whole nucleotide sequence of pCTX-M3 
had been previously elucidated, this probable 16S rRNA MT escaped 
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uncharacterized and unpublished until Galimand and colleagues named this new 
protein ArmA for aminoglycoside resistance methyltransferase A. It showed 
homology with those aminoglycoside resistance MTs from actinomycetes (identity 
levels of ArmA with these proteins ranging from 21% to 30%).  
 Only 4 months after the report of ArmA, another article describing a 16S 
rRNA MT in a gram-negative bacterium was published (Yokoyama et al., 2003). 
The 756 bp gene, designated rmtA (ribosomal RNA methyltransferase A), was 
identified in a P. aeruginosa strain isolated from a clinical sample in 1997 in Japan. 
This gene was found to confer high-level resistance to arbekacin, amikacin, 
gentamicin, kanamycin and tobramycin when cloned and expressed in E. coli and 
P. aeruginosa.  
 RmtB and RmtC acquired MTs were subsequently discovered for the first 
time also from Japanese hospitals. The first one was isolated from a Serratia 
marcescens strain in 2002, and published in 2004 (Doi et al., 2004). The resulting 
amino acid sequence of rmtB shared 82% identity with RmtA, and a methylation 
assay with histidine-tagged recombinant protein confirmed that RmtB was a 
functional 16S rRNA MT. The first identification of RmtC was published in 2006 
(Wachino et al., 2006b). It was found in a Proteus mirabilis strain isolated in 2003, 
and it was also confirmed to be a 16S rRNA MT conferring the same resistance 
pattern as ArmA, RmtA, or RmtB.  
 Successively, other 16S rRNA MTs have been discovered among gram-
negative bacteria to date. RmtD was firstly reported in 2007 from a clinical P. 
aeruginosa strain in Brazil (Doi et al., 2007c), and its variant RmtD2, which shows 
9 amino acid substitutions compared to RmtD, was found in Argentina in 2011 
(Tijet et al., 2011). The first and sole identification of the RmtE methyltransferase 
was published in 2010. It was found in E. coli bovine isolates from the United 
States (Davis et al., 2010). RmtF was identified in a K. pneumoniae clinical strain 
in Reunion Island in 2012 (Galimand et al., 2012), and RmtG and RmtH have been 
published in 2013 in K. pneumoniae isolates from Brazil and Iraq, respectively 
(Bueno et al., 2013; O’Hara et al., 2013). All the above mentioned 
methyltransferases are considered to be (or have been confirmed to be) N7-G1405 
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16S rRNA MTs. With the exception of NpmA, which was reported in 2007 in a 
clinical E. coli strain from Japan, and it was confirmed to methylate the 16S rRNA 
at position A1408. Additionally, it shows an appropriate resistance phenotype 
according to its function (Wachino et al., 2007). Nevertheless, this was the only 
time NpmA has been identified, and no other N1-A1408 MT has been reported in 
gram-negative bacteria to date.    
 Regarding the nomenclature of these acquired 16S rRNA MTs in gram-
negative bacteria, due to their emergence and increasing prevalence, in 2008, Doi 
and colleagues proposed some rules in order to prevent confusion over the 
nomenclature of 16S rRNA methylases (Doi et al., 2008b), to avoid cases such as 
the two existing nomenclature systems for aminoglycoside acetyltransferases. 
Hence, the following guidelines were suggested: a gene with an amino acid identity 
greater than 95% with the closest known 16S rRNA MT will be assigned a variant 
number starting from two (e.g. rmtD2). A gene that has between 50 and 95% 
amino acid identity with the closest known 16S rRNA MT will be assigned a new 
alphabet letter according to the closest existing gene name (e.g. rmtF, armB). A 
gene that either shows an amino acid identity of less than 50% with the closest 
known 16S rRNA MT or that is proven to methylate a new residue of 16S rRNA, 
may be assigned a completely new gene name (i.e, npmA).  
 
3.2.1.2- Clinical relevance and resistance phenotypes conferred by the 16S rRNA 
MTs 
 Despite the emergence of antimicrobial resistance, AGs retain broad-
spectrum activity against multidrug-resistant gram-negative bacilli. Thus, AGs 
often remain a useful weapon against those pathogens resistant to the first choice 
antibiotics. Even though modifying enzymes represent the most prevalent 
mechanism of AG resistance, many strategies have been employed to overcome the 
function of these enzymes. For instance, amikacin has been generally reserved for 
AG resistant pathogens because it escapes inhibition by most AMEs. Furthermore, 
arbekacin, available in Japan for the treatment of MRSA infections, is usually 
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stable despite enzymatic modification with the sole exception of the bifunctional 
enzyme AAC(6´)-APH(2´´). This modification, however, confers only low-level 
resistance to arbekacin (MIC between 4 and 32 mg/L).  
 Regardless of AMEs being the most frequent AG resistance mechanism, 
acquired 16S rRNA MTs rapidly came into the spotlight since their first 
identifications due to several factors (Doi and Arakawa, 2007). These include their 
expression by genes that are carried by mobile genetic elements or their association 
with other important resistance mechanisms, such as the recently described NDM-1 
carbapenemase). The main alarming factor was related to their function, since these 
acquired 16S rRNA MTs confer resistance to all AGs available in clinical settings, 
aditionally the 16S rRNA MTs-producing bacteria are able to grow under very high 
concentrations of AGs as compared with the MIC values detected for various 
AMEs. Even though it cannot be stated that acquired 16S rRNA MTs are only 
found in pathogenic bacteria, as they can also be found in gram-negative organisms 
that belong to the comensal microbiota, they are commonly detected in gram-
negative pathogens isolated from nosocomial and community acquired infections 
(Wachino and Arakawa, 2012). Moreover, some of the most prevalent bacterial 
species reported to produce 16S rRNA MTs (as for instance Klebsiella spp., A. 
baumanii, P. aeruginosa, and Enterobacter spp.) are encompassed in the so called 
ESKAPE pathogens. This group comprises multi-drug resistant strains of E. 
faecium, S. aureus, Klebsiella spp., A. baumannii, P. aeruginosa, and Enterobacter 
spp., and according to data from the Centers for Disease Control, the six ESKAPE 
bacteria are responsible for two-thirds of all healthcare associated infections (Rice, 
2008).       
 The N7-G1405 16S rRNA MTs (ArmA, RmtA-H) are able to confer high-
level resistance to 4,6-disubstituted DOS, such as gentamicin, amikacin, 
tobramycin, kanamycin, or even arbekacin. However, they do not reduce the 
susceptibility to apramycin (4-monosubstituted DOS), 4,5-disubstituted DOS, or 
streptomycin (non DOS) (Table 7). As a rule, when these genes are cloned and 
expressed in E. coli laboratory strains, the MIC values are ≥ 128 mg/L for all the 
4,6-disubstituted DOS, even though some differences among all the existing 
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publications to date can be found. It is not infrequent to find MICs >1024 mg/L to 
different 4,6-disubstituted DOS, much higher than the MIC breakpoints stated by 
EUCAST (where an MIC > 16 mg/L is considered resistant for amikacin, and an 
MIC > 4 mg/L is resistant to gentamicin and tobramycin). Nonetheless, in most of 
the reports the MIC of tobramycin is slightly lower as compared to other 4,6-
disubstituted DOS. In addition, wild-type strains bearing a N7-G1405 16S rRNA 
MT generally show MIC values > 1024 mg/L for all 4,6-DOS due to the co-
existence of the methyltransferase with some AMEs within the same strain.   
 In contrast, the only N1-A1408 16S rRNA MT identified to date in gram-
negative bacteria, NpmA, confers high-level resistance to the 4,5-disubstituted 
DOS (neomycin), 4-monosubstituted DOS (apramycin), but it also significantly 
reduces susceptibility to the 4,6-disubstituted DOS (Wachino et al., 2007) (Table 
7). This means that this type of MT is of even greater concern as it confers a 
broader range of aminoglycoside resistance.  
       
Table 7. Resistance phenotype conferred by acquired 16S rRNA MTs 
Acquired 16S rRNA MTs 
Aminoglycosides 
N7-G1405 N1-A1408 
4,6-DOS RR R 
4,5-DOS S RR 
Apramycin S RR 
Streptomycin S S 
RR, high-level resistance (MIC >128 mg/L); R, resistant (MIC >16 mg/L and 
< 128 mg/L); S, susceptible.  
 
 
 Regarding the screening procedure of 16S rRNA MT-producing bacteria, 
since the first identifications of these acquired enzymes, those strains showing 
resistance to AGs started to be further characterized by assaying their ability to 
grow in the presence of high concentrations of various AGs, as testing with only 1 
or 2 antibiotics would not be conclusive due to the AMEs. If we check among all 
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the existing reports on acquired MTs, an isolated strain is commonly considered to 
be a potential carrier of an N7-G1405 16S rRNA MT when it is able to grow with a 
concentration of different 4,6-DOS greater than 128 mg/L, but it remains 
susceptible to the 4,5-DOS and apramycin. Some authors proposed arbekacin as a 
useful AG to test for the presence of these MTs (Doi et al., 2004; Doi et al., 
2007b), as it is only modified by the bifunctional enzyme AAC(6´)-APH(2´´) 
(Fujimura et al., 2000). However, the combination of gentamicin and amikacin is 
the most frequently used for testing purposes. Along the same line, screening for an 
N1-A1408 16S rRNA MT would require a consistent phenotype of resistance to 
4,6-DOS and high-level resistance to 4,5-DOS and apramycin (Table 7). 
Furthermore, the identification of these MTs is more complex as its resistance 
profile against the clinically utilized AGs is very similar to that confeered by the 
co-production of multiple AMEs. Moreover, the high-level resistance to apramycin 
can be confused with the presence of AAC(3)-IV, which is the most prevalent gene 
for apramycin resistance in E. coli. Anyhow, phenotypic screening provides an 
initial approach and the only confirmatory method at present to detect the known 
16S rRNA MTs is PCR. All the aforementioned procedures are generally 
performed with isolates of Enterobacteriaceae, P. aeruginosa, and A. baumanii, 
and it is important to take the possibility of intrinsic high-level resistance not due to 
methylation in certain opportunistic bacteria into account, such as 
Stenotrophomonas maltophilia.         
 
3.2.1.3- Intrinsic vs. acquired 16S rRNA MTs  
 Based on sequence similarity, all MTs intended to methylate residue G1405 
on the 16S rRNA are categorized as 16S rRNA MTs with an FmrO domain. 
However, the classification of 16S rRNA MTs into four distinct families depending 
on their origin and target has been previously proposed (Conn et al., 2009): “Kgm” 
family (kanamycin-gentamicin MTs) are intrinsic MTs of residue G1405, “Arm” 
family (aminoglycoside resistance MTs) are acquired MTs of G1405, “Kam” 
family (kanamycin-apramycin MTs) are intrinsic MTs targetting A1408, and 
“Pam” family (pan-aminoglycoside resistance MTs) are acquired MTs of residue 
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A1408. Thus, those acquired methyltransferases belonging to the Arm family 
(ArmA, RmtA-H) would be the equivalent to the Kgm family of the producers, and 
NpmA (Pam family) would be in the Kam family MTs.  
 Concerning the phylogenetic relatedness of the acquired 16S rRNA MTs, 
the percentage of amino acid identity between the Arm family members (ArmA, 
RmtA-H) range from 20% to 81%, whereas NpmA shares a low identity with MTs 
of the Arm family (Table 8).  
 
Table 8. Percentage of identity among amino acid sequences of acquired 16S rRNA MTs 
 Amino acid sequence identity (%) 
16S rRNA 
MT ArmA RmtA RmtB RmtC RmtD/D2 RmtE RmtF RmtG RmtH NpmA 
ArmA 100 27 27 29 20/25 27 22 24 26 10 
RmtA  100 81 30 39 35 42 35 63 12 
RmtB   100 28 39/38 32 42 35 64 11 
RmtC    100 27/29 28 26 22 28 5 
RmtD/D2     100/96 31/32 44/46 57/59 38 9 
RmtE      100 32 28 28 5 
RmtF       100 36 39 2 
RmtG        100 30 5 
RmtH         100 5 
NpmA          100 
Relatedness among all the acquired MTs. The highest similarities for each MT are highlighted.    
 
 When comparing the amino acid identity shared by all the 16S rRNA MTs, 
the G1405 methyltransferases cluster together, and so do those methylating the 
position A1408 (Figure 10), however, the acquired MTs share less than 33% amino 
acid identity with the equivalent group of intrinsic MTs. In relation to the G+C 
contents of 16S rRNA MTs genes, most MT genes from aminoglycoside-producing 
isolates (gram-positive) have a G+C content ranging from 64% to 72% (Liou et al., 
2006), whereas the G+C content of the first reported acquired MT genes is around 
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30%-59%. Therefore it was hypothesized that the origin of the acquired MTs is 
unlikely to be the aminoglycoside-producing actinomycetes (Liou et al., 2006). 
However, there are certain low G+C content gram-positive bacilli able to produce 
aminoglycosides (i.e., B. circulans). As it is known that genes from gram-negative 
bacteria are not generally expressed in gram-positive organisms, Liou and 
colleagues cloned and expressed armA with its putative promoter in Bacillus 
subtilis where it conferred resistance, giving rise to the conjecture of how armA 
could have originated from aminoglycoside-producing low G+C content gram-
positive bacteria (Liou et al., 2006). Nonetheless, the origin of these acquired 16S 
rRNA MTs remains unknown.  
 Regarding the determination of the target nucleosides for both groups of 
16S rRNA MTs (intrinsic and acquired), there have been already several studies 
with the aim of ascertaining the exact position these MTs methylate (Beauclerk and 
Cundliffe, 1987; Gutierrez et al., 2012; Holmes and Cundliffe, 1991; Liou et al., 
2006, Savic et al., 2009). In general, this is experimentally performed by primer 
extension methodology, which makes it possible to determine the methylated 
residue (N7-G1405, N1-A1408), and Matrix-assisted laser desorption/ionization 
mass spectrometry (MALDI-MS), which can measure the presence or absence of a 
methyl group (by reading a mass difference of 14 Da.) and therefore confirm if a 
methylation occurs (Gutierrez et al., 2012). The methylation sites have been 
assessed for some intrinsic 16S rRNA MTs, such as KgmB (G1405), Sgm 
(G1405), GrmA (G1405), Krm (G1405), KamA (A1408), and KamC (A1408). In 
relation to the acquired 16S rRNA MTs, N7-G1405 has been confirmed to be the 
methylated residue for ArmA, RmtB, RmtC, and RmtF, whereas NpmA has been 
determined to methylate at position N1-A1408. These acquired enzymes have a 
methyltransferase activity specific for the bacterial 30S ribosomal subunit 
consisting of 16S rRNA and several ribosomal proteins, but not for the naked 16S 
rRNA, which indicate that ribosomal proteins play a crucial role in the precise 
substrate recognition. The methylation step takes place before the binding of the 
two ribosomal subunits (Wachino et al., 2010).  
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3.2.2- Epidemiology of acquired 16S rRNA MTs 
 
3.2.2.1- Prevalence and distribution  
 Despite data on the prevalence of aminoglycoside resistance mediated by 
16S rRNA methylation in gram-negative bacteria remaining scarce for the first 3 or 
4 years following their first identification, an increase in available data has now 
Figure 10. Dendrogram with the acquired 16S rRNA MTs and a selection of AG 
resistance MTs from the producers, as well as the indigenous MT of E. coli, KsgA. 
Green: acquired MTs of the G1405; blue: acquired MT of the A1408. The bar 
denotes genetic distance. Bootstrap values are the result of 1000 iterations.   
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been observed, mainly due to the existence of surveillance programs. Information 
obtained from global antimicrobial surveillance studies is important to establish 
trends in antimicrobial resistance in bacteria, although local studies constitute a 
significant part of the recovered data. Surveillance programs vary widely in that 
some programs focus on specific pathogens, whereas other programs focus on 
specific antimicrobial agents. One of the most important surveillance programs of 
antimicrobial resistance is the SENTRY Antimicrobial Surveillance Program. This 
is an ongoing international program that was initiated in 1997 to monitor the 
occurrence and antimicrobial susceptibility of bacterial pathogens causing 
nosocomial and community-acquired infections (Masterton, 2008). Sentinel sites 
are present in more than 30 countries worldwide, and this program has generated 
more than 180 publications thus far.  
 Although resistance mediated by 16S rRNA MTs has been increasingly 
reported worldwide (Figure 11), the distribution of these MTs is still poorly 
defined, with little molecular epidemiology data from recent collections. 
Nevertheless, acquired 16S rRNA MTs seem to be most prevalent in Asian 
countries. SENTRY data for 2007-2008 indicated prevalence rates of 
aminoglycoside resistance due to methylation among Enterobacteriaceae of 10.5% 
in India, 6.9% in China, 6.1% in Korea, 5% in Taiwan, and 3.1% in Hong Kong 
(Livermore et al., 2011). However, there are many reports generated at the local 
level from different hospitals and institutions worldwide, and regardless of the 
variability observed between hospitals, when taken as a whole, the highest 
prevalence is found in Asian countries. Additionally, local surveys have provided 
useful data describing the role of reservoirs such as animals or the environment in 
the distribution of acquired 16S rRNA MTs, as well as on the molecular genetics 
involved in their spread. Surprisingly, there are not as many reports from America 
as there are in Asia or Europe, and they are generally associated with non-
fermentative gram-negative bacilli (A. baumannii, P. aeruginosa) (Doi et al., 
2007b; Fontes et al., 2011). Little information is available on the distribution of 
acquired MTs in Africa, as up to now there are only 3 publications from Algeria 
and Kenya (Bouzidi et al., 2011; Naas et al., 2011; Poirel et al., 2011c).  
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 When comparing the global prevalence of the known acquired 16S rRNA 
MTs, an evident division can be observed. Hence, ArmA and RmtB have been the 
most prevalent MTs by far, whereas RmtA, the one firstly identified with ArmA, 
has only been reported 4 times (Yokoyama et al., 2003; Yamane et al., 2007; Jin et 
al., 2009; Poirel et al., 2011b), and RmtE, RmtF, RmtG, RmtH, and NpmA, have 
been only identified once (Wachino et al., 2007; Davis et al., 2010, Galimand et 
al., 2012; Bueno et al., 2013; O’Hara et al., 2013). RmtC and RmtD are considered 
MTs with a low prevalence, however, there has been a clear increase in the number 
of publications reporting RmtC in the last years (Figure 11). Commonly, a single 
acquired MT is produced by one strain, although several reports have described the 
co-production of both ArmA and RmtB, or ArmA and RmtC by the same isolate 
(Ma et al., 2009, Mushtaq et al., 2011).  
 Concerning the highly prevalent acquired MTs, ArmA has been reported in 
several Asian and European countries, Algeria in Africa, Australia, and in the USA 
(Galimand et al., 2005; Gonzalez-Zorn et al., 2005b; Bogaerts et al., 2007; Folster 
et al., 2009; Ma et al., 2009; Poirel et al., 2010; Karah et al., 2011; Livermore et 
Figure 11. A graph representing the number of publications concerning each acquired 16S 
rRNA MT per year since their first identification in 2003.  
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al., 2011a; Moissenet et al., 2011; Naas et al., 2011; Poirel et al., 2011d; 
Samuelsen et al., 2011; Sekizuka et al., 2011; Sung et al., 2011; Zacharczuk et al., 
2011; McGann et al., 2012; Guo et al., 2012; Mezzatesta et al., 2013; Saule et al., 
2013; Sonnevend et al., 2013; Tada et al., 2013c) (Figure 12). In Asia, it has been 
found in Japan, South Korea, China, Taiwan, Vietnam, Pakistan, Bangladesh, 
India, Afghanistan, Oman, and in the United Arab Emirates. Amongst these, the 
prevalence of ArmA is highest in South Korea, Taiwan, China, and Vietnam. In 
Europe, ArmA is present in Spain, France, Italy, Belgium, United Kingdom, 
Norway, Sweden, Latvia, Serbia, Poland, and Bulgaria, the last two reaching the 
highest prevalence rates. RmtB distribution is also scattered worldwide, although 
as compared with ArmA, RmtB prevalence and spread in Europe is low and it has 
only been found in France, Belgium, and Greece (Berçot et al., 2008; Périchon et 
al., 2008; Galani et al., 2011). In addition, it has been occasionally isolated in the 
USA, Mexico, Brazil, Australia, Turkey, Bangladesh, Pakistan, Vietnam and 
Japan, while it is highly prevalent in China, South Korea, and Taiwan (Doi et al., 
2004; Fritsche et al., 2008; Ma et al., 2009; Park et al., 2009; Berçot et al., 2010; 
Poirel et al., 2010; Bogaerts et al., 2011; Deng et al., 2011a, 2011b; Poirel et al., 
2011; Tada et al., 2013). Among the lowly prevalent acquired MTs, RmtC has only 
been found a few times but its distribution is spread out (i.e. USA, United 
Kingdom, Kenya, India, Bangladesh, Japan, Australia and New Zealand) (Wachino 
et al., 2006; Zong et al., 2008; Folster et al., 2009; Hopkins et al., 2010; Poirel et 
al., 2011c; Islam et al., 2012; Williamson et al., 2012), whereas the few isolates 
bearing RmtA are mostly gathered around Asia (India, South Korea, and Japan) 
(Yokoyama et al., 2003; Jin et al., 2009; Poirel et al., 2011b), and those with 
RmtD/D2 have only been found in South America (Chile, Argentina, and Brazil) 
(Fritsche et al., 2008). Moreover, RmtD is considered to be highly prevalent in 
Brazil (Doi et al., 2007d).    
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3.2.2.2- Reservoirs and routes of transmission  
 After so much literature on how aminoglycoside-producing bacteria avoid 
death by methylation of the 16S rRNA, an evident question arose in the field of 
aminoglycoside resistance: why this mechanism had not been found in clinically 
relevant bacteria exposed to aminoglycosides? There was no certainty of whether it 
did not exist or it was simply missed because of the screening methods, which may 
lead it to be confused with the production of multiple AMEs. Once ArmA and 
RmtA were initially reported in 2003 from strains of K. pneumoniae and P. 
aeruginosa, respectively, and they were confirmed to confer a high-level resistance 
to all 4,6-DOS when cloned and expressed in E. coli, an in depth search for 16S 
rRNA MTs in different gram-negative bacilli originated.  
 The most prevalent and distributed enzymes, ArmA and RmtB, have 
generally been found among species of Enterobacteriaceae (Table 9). In addition, 
ArmA and RmtB have occasionally been isolated from non-fermentative gram-
negative bacilli, such as P. aeruginosa or A. baumanii, which are nosocomial 
 Figure 12. Map indicating the global distribution and prevalence of the acquired 16S rRNA 
MTs from their first identification until now. Isolates belonging to those publications that 
constitute this Thesis are not included. Those cases where alternative sources other than humans 
are represented (e.g. pigs, chickens, cattle, pets, food, or environment) means that one or more 
isolates (even all of them) are from that source.     
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pathogens of global concern (Gurung et al., 2010; Tada et al., 2013c). In the case 
of RmtA or RmtD, most strains found are P. aeruginosa as compared with the 
other acquired MTs, which are mostly detected in Enterobacteriaceae strains (Doi 
et al., 2007b; Jin et al., 2009). For a long time, RmtC was thought to be present 
only in P. mirabilis, as it was initially identified in a P. mirabilis strain in Japan 
(Wachino et al., 2006b), two years later in P. mirabilis from Australia (Zong et al., 
2008), and then there were no more reports until its discovery in Salmonella 
enterica isolates (Hopkins et al., 2010). Acquired 16S rRNA MTs have only been 
found in gram-negative bacteria, but not in gram-positives. This led to the question 
of whether or not these enzymes are functional in gram-positive bacteria. Hence, 
two laboratories have confirmed that ArmA and RmtC confer high-level resistance 
to 4,6-DOS AGs when cloned and expressed in B. subtilis, and B. subilis and S. 
aureus, respectively (Liou et al., 2006; Wachino et al., 2010).      
 The acquired 16S rRNA MTs have mostly been identified in human strains 
isolated from either nosocomial or community-acquired infections. Nonetheless, 
the early detection of ArmA in a single E. coli isolated from a farm pig (Gonzalez-
Zorn et al., 2005b) raised the question of whether other sources such as animals or 
food products can be involved in the origin or spread of acquired 16S rRNA MTs. 
ArmA, RmtB, and RmtE are the only MTs identified from animals to date. ArmA 
has been reported from pig isolates in Spain and South Korea (Gonzalez-Zorn et 
al., 2005b; Choi et al., 2011), from cattle in South Korea (Choi et al., 2011), and 
from chickens in China and South Korea (Choi et al., 2011; Du et al., 2012) 
(Figure 12). In China, RmtB has been widely associated to pigs, chickens, and 
cattle, but also livestock-farming environments and pet animals (Deng et al., 
2011a, 2011b; Li et al., 2012; Du et al., 2012) (Figure 12). The only description of 
RmtE was from E. coli recovered from cattle (Davis et al., 2010). Regarding other 
sources, RmtD was detected in a bacterium isolated from a Brazilian river (Fontes 
et al., 2011), additionally RmtC was found in a S. enterica sample collected from 
food in the UK (Hopkins et al., 2010) (Figure 12). Moreover, both the strains 
recovered from a river and from food were clonally related to the human strains 
carrying the respective MT, indicating a clear link between the different sources of 
transmission for this resistance mechanism.          
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3.3- Genetic background of acquired 16S rRNA methyltransferases 
 
3.3.1- Location of the 16S rRNA MT genes 
 One of the issues that raises concerns about the known acquired 16S rRNA 
MTs is that their structural genes are generally located within transferable plasmids 
instead of the chromosome, which leads to the possibility of vertical but also 
horizontal transfer, thus accelerating their spread. The armA and rmtB genes have 
Table 9. Bacterial species in which the acquired MTs had been found to date*  
Acquired 16S rRNA 
methyltransferase Bacterial species 
ArmA 
Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia 
coli, Enterobacter aerogenes, Enterobacter cloacae, 
Serratia marcescens, Citrobacter freundii, Citrobacter 
amalonaticus, Proteus mirabilis, Shigella flexneri, 
Salmonella enterica, Providencia stuartii, Pseudomonas 
aeruginosa, Acinetobacter baumanii, Acinetobacter 
calcoaceticus 
RmtA P. aeruginosa, K. pneumoniae 
RmtB 
E. coli, K. pneumoniae, E. cloacae, E. aerogenes, 
Enterobacter amnigenus, P. mirabilis, C. freundii, S. 
marcescens, A. baumannii 
RmtC P. mirabilis, S. enterica, E. coli, K. pneumoniae, P. stuartii 
RmtD/D2 
P. aeruginosa (D), K. pneumoniae (D, D2), E. cloacae 
(D, D2), Enterobacter agglomerans (D2), C. freundii (D, 
D2), P. mirabilis (D2) 
RmtE E. coli 
RmtF K. pneumoniae 
RmtG K. pneumoniae 
RmtH K. pneumoniae 
NpmA E. coli 
* Isolates from the publications constituting this Thesis are not included 
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not been found chromosomally located thus far, regardless of the high number of 
strains that harbor these methyltransferases. In addition, the few reports of rmtA 
and the single identification of npmA proved that these genes are borne by 
conjugative plasmids (Yokoyama et al., 2003; Yamane et al., 2007; Wachino et al., 
2007; Jin et al., 2008). On the other hand, rmtE, rmtF and rmtG have been 
discovered on plasmids that cannot be transferred by conjugation (Davis et al., 
2010; Galimand et al., 2012; Bueno et al., 2013). The only work describing rmtH 
states that it is likely located on the chromosome. Interestingly, rmtD, which is 
highly prevalent in South America, has always been found to be chromosomally 
located among various clonally related P. aeruginosa strains, whereas rmtD2 was 
observed to spread in Argentina among non-related strains and could be transferred 
by conjugation. rmtC was initially found to be borne by a plasmid in a P. mirabilis 
strain, but was pointed out to be chromosomally located in a S. enterica clone 
spread in the UK.    
      
3.3.1.1- Plasmids carrying acquired 16S rRNA MTs 
 In most cases acquired 16S rRNA MTs are plasmid-mediated. Classifying 
plasmids into groups based on their phylogenetic relatedness is helpful to analyze 
their distribution but also to assess their relationship to host cells (Carattoli, 2009). 
In 1971, Datta and Hedges proposed a plasmid categorization scheme on the basis 
of plasmid stability during conjugation (Datta and Hedges, 1971). They defined the 
term “Incompatibility” as the inability of two related plasmids that share a common 
replication control to be propagated in the same cell line, and therefore those 
plasmids would belong to the same “Incompatibility group”. Since 2005, a PCR-
based replicon typing scheme has been available to target the replicons of the major 
plasmid families occurring in Enterobacteriaceae (Carattoli et al., 2005). The main 
incompatibility groups in Enterobacteriaceae are HI1, HI2, I1, X, L/M, N, FIA, 
FIB, FIC, W, Y, P, A/C, T, K, and B/O (Carattoli, 2009). Among these, the ones 
mainly associated with antibiotic resistance genes are F, A/C, L/M, I1, HI2, and N.   
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 Plasmid-mediated 16S rRNA MTs are usually borne by plasmids belonging 
to the IncA/C, IncN, IncL/M, and IncF groups (Table 10). IncA/C plasmids have 
been thoroughly studied in the last 10 years, since they have been found to be the 
primary plasmids responsible for the spread of the blaCMY-2 cephalosporinase gene 
prevalent among E. coli and Salmonella spp. isolates in North America and Europe 
(Carattoli et al., 2012). They are broad host range plasmids, therefore they can 
replicate in Enterobacteriaceae but also in Photobacterium damselae and 
Aeromonas salmonicida.  IncA/C-type plasmids have been detected in strains from 
humans as well as from animals. IncN plasmids have mainly been associated with 
strains of animal origins, additionally they are involved in the transmission of the 
blaCTX-M-1 gene, which suggests an animal reservoir for this ESBL. These plasmids 
are highly prevalent in E. coli from the avian faecal flora and in Salmonella spp. 
from retail meat and food-producing animals (Johnson et al., 2007). Plasmids 
belonging to the IncL/M family are broad-host-range and have been associated 
with the spread of blaCTX-M-3 among human strains in Poland, pCTX-M-3 being the 
representative plasmid of this family (Baraniak et al., 2002). The IncF-type 
plasmids are low-copy-number plasmids limited to the Enterobacteriaceae by their 
host-range. They are not a homogeneous group, presenting a large variation in size 
(from 50 to 200 kb), and they often carry more than one replicon, as they can carry 
the repFII replicon alone or in combination with repFIA and/or repFIB. These IncF 
plasmids have widely been associated with the dissemination of the pandemic 
CTX-M-15 β-lactamase (Woodford, 2008).    
 The armA gene was found to be located on IncA/C and IncHI2 plasmids in 
Asian strains isolated before 2001, but later on it became prevalently linked to 
IncF, IncL/M, and untypeable plasmids (Kang et al., 2008). It was suggested that 
this plasmid transition was responsible for the emergence of multidrug-resistant K. 
pneumoniae in these countries (Carattoli, 2009). At that time, IncL/M plasmids 
were associated with the dissemination of the armA gene in clinical isolates from 
European countries, pCTX-M-3 specifically was considered to be responsible for 
the spread of this acquired MT in Poland (Zacharczuk et al., 2011). However, it is 
important to highlight that armA was located on an IncN plasmid from an animal 
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origin in Spain (Gonzalez-Zorn et al., 2005a), and more recently, the emergence of 
NDM-1-positive IncA/C plasmids bearing armA has been described.  
 
Table 10. Main plasmid incompatibility types found to bear a MT genea  
Acquired 16S rRNA 
MT gene Plasmid Incompatibility group 
armA IncL/M (blaCTX-M-3
b, blaCTX-M-15), IncHI2, IncN, IncA/C 
(blaNDM-1), IncF (blaKPC-2, qnrB4) 
rmtA IncA/C (blaNDM-1) 
rmtB 
IncI1, IncA/C, IncFI (qepA), IncFII (qepA, qnrS1, 
fosA3, blaCTX-M-15), IncF49:A-:B- (qnrS1, blaCTX-M-15, 
aac(6´)-Ib-cr), IncF33:A-:B- (blaCTX-M-9), IncF2:A-:B- 
(qepA)   
rmtC IncA/C (blaNDM-1) 
rmtD/D2 IncA/C 
rmtE NDc 
rmtF Non-typable 
rmtG IncN, IncL/M, IncA/C 
rmtH chromosomally located 
npmA ND 
a Isolates from the publications constituting this Thesis are not taken into consideration 
b Other important resistance determinants co-located on the same plasmid  
c Not determined 
                   
 Despite the rmtB gene having been shown to be located on different 
replicons such as IncI1 or IncA/C, the fully sequenced IncF plasmid pIP1206 from 
an E. coli isolated in France revealed the presence of both rmtB and qepA genes, 
the latter encoding a novel plasmid-mediated fluroquinolone efflux pump 
(Périchon et al., 2008). Since then, rmtB has mostly spread out in China, linked to 
plasmids of the IncF family which have been further characterized following a 
typing scheme used to discriminate IncF variants (Villa et al., 2010) (Table 10). 
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Most of these rmtB carriers are IncFII variants (Deng et al., 2011b). For instance, 
F33:A-:B- and F2:A-:B- plasmids mediate the dissemination of rmtB associated 
with CTX-M-9 ESBLs and QepA genes, respectively (Deng et al., 2011a). 
Regarding the rest of the acquired MT genes, IncA/C may be the main 
incompatibility group found in association to these genes (Table 10).   
 
3.3.2- Mobilization platforms and close genetic environment of acquired 16S 
rRNA MTs 
 The genetic environment of 16S rRNA MT genes has been elucidated in 
some cases. Deciphering these environments is crucial because it will contribute to 
the understanding of how genetic elements involved in the mobilization of these 
genes accelerate their spread. Furthermore, it will aid in the prediction of the 
evolutionary pathways of these resistance determinants. Below, the genetic regions 
clarified so far are outlined, and the mobile elements associated with each MT gene 
are summarized in Table 11.   
- armA. Although it is the most prevalent acquired MT to date, its genetic context 
has only been elucidated in certain strains. All armA surroundings analyzed to date 
share a high identity. Usually armA is found flanked by two transposases taking 
part in the Tn1548 composite transposon, which comprises amongst others, a class 
1 integron and an ISCR1 element upstream of armA. After the earliest 
identification of ArmA, its gene was shown to be disseminating among different 
human strains in Europe in the same Tn1548 structure as the pCTX-M-3 plasmid 
(Galimand et al., 2005; Golebiewski et al., 2007). However, the complete sequence 
of plasmid pMUR050, from an animal isolate in Spain (Gonzalez-Zorn et al., 
2005a), revealed that armA was located on a Tn1548 lacking a dhfrXII 
trimethoprim resistance cassette. Recently, a few other armA-containing regions 
have been published (Du et al., 2010; Jiang et al., 2010; Ho et al., 2011), and all of 
them are related to Tn1548.  
- rmtA. The genetic environment of rmtA has been elucidated in different strains of 
P. aeruginosa (Yamane et al., 2004), and although not identical, rmtA is embedded 
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in a region that shares similarity with the composite transposon Tn5041, previously 
described to be involved in mercury resistance in Pseudomonas spp.  In addition, 
rmtA is bracketed by two copies of a kappa-gamma (κγ) mobile element previously 
shown to belong to the Tn3 family of transposons, known for containing several 
transposase and resolvase genes. Therefore, it was hypothesized that after the first 
insertion of rmtA into a Tn5041, the latter was responsible for its spread among 
Pseudomonas spp. strains (Yamane et al., 2004).     
- rmtB. This MT gene has generally been found on fragments flanked by two IS26 
insertion sequences, associated with Tn3 transposon structures and ISCR3 
elements. It is frequently accompanied by a Tn3-like structure containing an 
upstream blaTEM-1, as well as the downstream fluoroquinolone efflux transporter 
gene, qepA (Perichon et al., 2008; Li et al., 2012).  
- rmtC. When it had only been found in P. mirabilis, the presence of an ISEcp1 
element at the 5’ end of rmtC was deciphered. This element was shown to contain a 
transposase gene responsible for the transposition of rmtC, as well as to promote its 
expression (Wachino et al., 2006a). When this MT was discovered in S. enterica 
isolates from the UK, the presence of an ISEcp1 immediately upstream of rmtC 
was found when amplifying a DNA fragment from rmtC to the end of ISEcp1 by 
using the primers previously described (Zong et al., 2008). However, the complete 
ISEcp1 element could not be amplified by using internal primers, indicating either 
a partial deletion or the involvement of a different ISEcp1-like element in the 
dissemination of rmtC in Salmonella (Hopkins et al., 2010). At the same time, the 
report of RmtC in Salmonella isolates from the USA identified the 3´end of the 
ISEcp1 along with one inverted repeat region upstream of rmtC, but its whole 
sequence remains uncertain (Folster et al., 2009).   
- rmtD/D2. The genetic environment of rmtD was investigated in P. aeruginosa 
and K. pneumoniae strains (Doi et al., 2008a). In both cases the rmtD gene is 
bound by 2 copies of an ISCR14 element in the same orientation, and a 
downstream class 1 integron follows rmtD. In K. pneumoniae, both copies of 
ISCR14 are truncated with an IS26 element, thus rmtD appears to have been 
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mobilized from P. aeruginosa by an IS26-mediated event. The genetic surrounding 
of rmtD2 was similar to that of rmtD in P. aeruginosa (Tijet et al., 2011).   
 
Table 11. Genetic elements potentially involved in the 
mobilization of the 16S rRNA MT genes.     
Acquired 16S rRNA 
MT gene Mobile genetic element 
armA Tn1548, IS26 
rmtA Tn5041 
rmtB IS26, Tn3, ISCR3 
rmtC ISEcp1 
rmtD/D2 ISCR14, IS26 
rmtE NDa 
rmtF insE 
rmtG ND 
rmtH ISCR2 
npmA IS26 
a Not determined 
               
- rmtF. Its close environment consists of an insE transposase downstream of rmtF 
followed by an oriIS duplicated immediately upstream of rmtF. There were also an 
aminoglycoside resistance aac(6’)-Ib and a chloramphenicol resistance cat gene 
within the cloned fragment containing rmtF. 
- rmtH. In its first and only description, rmtH is located in the chromosome and 
bracketed by two copies of ISCR2 (O´Hara et al., 2013). ISCR2 is an IS91-like 
transposable element that has been found in association with several resistance 
genes and it is considered to facilitate the mobilization of downstream genetic 
elements (Toleman et al., 2006).   
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- npmA. In its first and only identification, this gene was located on a 9.1 kb 
fragment enclosed by two IS26 elements in the same orientation. This region does 
not share similarity with any other sequence in the database, but its vicinity shows 
a significant likeness with that of different multidrug-resistance plasmids 
sequences deposited in GenBank (Wachino et al., 2007).    
- rmtE, rmtG. The genetic context of these two genes has not yet been elucidated.    
 
3.4- Association of the acquired 16S rRNA MTs with other antibiotic 
resistance mechanisms 
 The emergence of acquired 16S rRNA MTs in gram-negative bacteria is of 
a great concern because aminoglycosides are still useful antibiotics for the 
treatment of several infections due to both gram-negative and gram-positive 
bacteria, but also, their use has been strongly encouraged as an alternative for those 
infections caused by bacteria resistant to other antibiotics (Livermore et al., 2011a). 
As previously described, acquired 16S rRNA MT genes are usually found within 
large conjugative plasmids, which possess the ability of accumulating various 
antibiotic resistance genes. Thus, acquired 16S rRNA MTs-producing bacteria are 
known to potentially develop multidrug resistance, their association to quinolone 
and β-lactam resistance being the most worrisome. Furthermore, they can either be 
co-produced by the same bacteria, or linked to the same genetic structure.   
- Association with quinolone resistance determinants 
    Quinolones are bactericidal agents widely used in human and veterinary 
medicine. They are divided into first generation quinolones (such as nalidixic acid), 
and second generation quinolones also called fluoroquinolones (such as 
norfloxacin or ciprofloxacin). Both groups show a high activity agains gram-
negative bacteria, and fluoroquinolones were developed to exhibit an increased 
action towards gram-positive bacteria (Jacoby, 2005). Besides the largely known 
quinolone resistance mechanism, which is chromosomally encoded and functions 
by mutating the antibiotic target site (DNA gyrase and Topoisomerase IV), in the 
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last decade the emergence of plasmid-mediated quinolone resistance (PMQR) 
further raised the significance of antibiotic resistance (Poirel et al., 2012). The 
PMQRs discovered so far are Qnr, which protects the DNA gyrase and 
Topoisomerase IV from quinolone binding; the AAC(6’)-Ib-cr, an aminoglycoside 
modifying enzyme variant able to acetylate ciprofloxacin; and the efflux pump 
QepA, that causes a significant decrease in susceptibility to the hydrophilic 
quinolones (i.e., ciprofloxacin, enrofloxacin).    
 PMQR has been associated with acquired 16S rRNA MTs in strains 
producing ArmA, RmtB, or RmtC. The latter has only been found in association 
with PMQR in two K. pneumoniae strains recently isolated from Bangladesh, 
which co-produce QnrB (Islam et al., 2012). ArmA has only been reported in 
association with PMQR a few times despite its high prevalence, most of which 
were in China (Jiang et al., 2010; Du et al., 2012; Guo et al., 2012; McGann et al., 
2012). It has been found to be co-produced with QnrS1, QnrB4, QnrA, QnrB2, and 
the enzyme AAC(6’)-Ib-cr, the last two of which were detected in chicken isolates. 
On the other hand, most RmtB reports are associated with the emergent efflux 
pump QepA, initially detected during a screening for aminoglycoside resistance 
MTs (Perichon et al., 2007). In addition, RmtB has been found with the aac(6´)-Ib-
cr variant as well as with several qnr genes of the A, B, and C variants. Moreover, 
in some cases the co-expression of several PMQR determinants coupled with 
RmtB has been observed (Liu et al., 2008). Most of the publications concerning 
RmtB linked to PMQR arise from bacteria isolated from animals (Liu et al., 2008; 
Deng et al., 2011a, 2011b). 
- Association with β-lactam resistance determinants 
 Given that β-lactams are one of the main families of antibiotics classified 
by the World Health Organization as critically important for the human medicine, 
the acquisition of β-lactam resistance determinants by gram-negative bacteria 
producing 16S rRNA MTs is a great cause for alarm. Besides the narrow and broad 
spectrum β-lactamases, such as a number of TEM and SHV enzymes as a 
resistance mechanism to penicillins, and first and second generation 
cephalosporins, the emergence and increase of ESBLs (Extended-spectrum β-
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lactamases), acquired AmpC enzymes, and carbapenemases in the last years pose a 
major concern regarding antibiotic resistance. In fact, it has been suggested that co-
selection with other resistance mechanisms (i.e., fluoroquinolones or 
aminoglycosides) may have contributed to this issue (Coque et al., 2008).   
 Regardless of the variety of existing ESBLs, since their first identification 
the acquired 16S rRNA MTs have mainly been found in CTX-M-type producers 
(Table 12). Among these, the association with the globally prevalent CTX-M-15 
variant has increasingly been reported in the last years (Table 15). But without a 
doubt, the emergence of carbapenem resistant bacteria in the last years and the 
recent findings on the coproduction of other resistance mechanisms such as the 16S 
rRNA MTs, are of a great concern. The main reason is that carbapenemases exhibit 
activity against a wide spectrum of β-lactams, including newer cephalosporins and 
carbapenems, which limits the few existing alternative options (i.e., 
aminoglycosides) for the treatment of these serious infections. Acquired 16S rRNA 
MTs have been found sporadically in bacteria producing SPM-1, IMP, and VIM 
metallo-β-lactamases (MBLs) (Doi et al., 2007c; Lee et al., 2007; Gurung et al., 
2010; Livermore et al., 2011a). Most worrisome is the increasing number of 
reports of 16S rRNA MTs among OXA-type and KPC-type carbapenemases in the 
last years. Both ArmA and RmtB have repeteadly been identified in association 
with KPC-type carbapenemases, of great overall relevance in K. pneumoniae 
infections (Jiang et al., 2010; Sheng et al., 2012), whereas an emergence of ArmA 
in OXA-type producing A. baumanii worldwide has been observed, with an 
increased incidence in Asian countries (Doi et al., 2007b; Kumarasamy et al., 
2010; Karah et al., 2011; Livermore et al., 2011a). In addition, NDM-1 (New Delhi 
Metalo β-lactamase-1), firstly reported in 2009, has become a major global health 
issue due to its rapid spread and resistance spectrum (Kumarasamy et al., 2010). 
Nowadays, the existence of NDM-producers with 16S rRNA MTs has already been 
reported. Furthermore, this linkage is usually associated to large multiresistant 
conjugative plasmids, and it appears to be a growing problem worldwide 
(Livermore et al., 2011b; Solé et al., 2011; Dortet et al., 2012; Dolejska et al., 
2013). 
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Table 12. Coproduction of acquired 16S rRNA MTs and ESBLs. 
Bacteria MT genes ESBL genes Country  
Year of 
Publication Reference 
K. pneumoniae armA  blaCTX-M-3 
France 2003 Galimand et al. 
E. coli, K. 
pneumoniae armA 
blaCTX-M-3, blaCTX-M-14,  
blaSHV-5 
Taiwan 2004 Yan et al. 
Enterobacteriaceae armA, rmtB 
blaCTX-M-3, blaCTX-M-9, 
blaCTX-M-14,  blaSHV-12 
 
Korea 2006 Park et al. 
Enterobacteriaceae armA, rmtB blaCTX-M-3,  blaCTX-M-14 Belgium 2007 Bogaerts et al. 
Enterobacteriaceae armA blaCTX-M-3 Poland 2007 Golebiewski et al. 
Providencia spp. armA blaPER-1 Korea 2007 Lee et al. 
Proteus mirabilis rmtC blaVEB-6 Australia 2008 Zong et al. 
P. mirabilis armA, rmtB blaCTX-M-3, blaCTX-M-4 Taiwan 2008 Wu et al. 
Enterobacteriaceae armA blaCTX-M-3 Bulgaria 2008 Sabtcheva et al. 
K. oxytoca armA blaCTX-M-15 China 2008 Zhang et al. 
Enterobacteriaceae armA, rmtB blaCTX-M-3, blaCTX-M-14 Korea 2008 Kang et al. 
A. baumanii armA blaPER-1 Korea 2008 Kim et al. 
Enterobacteriaceae armA, rmtB blaCTX-M-3, blaCTX-M-14 France 2008 Berçot et al. 
E. coli armA, rmtB blaCTX-M-14,  blaCTX-M-65 China 2009 Du et al. 
K. pneumoniae armA blaSHV-12 China 2009 Liu et al. 
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K. pneumoniae armA, rmtB 
blaCTX-M-3, blaCTX-M-14,  
blaCTX-M-15,  blaSHV-5,  
blaSHV-12 
Taiwan 2009 Ma et al.  
K. pneumoniae armA, rmtB blaCTX-M-14,  blaCTX-M-15 China 2009 Yu F. et al. 
E. coli rmtB 
blaCTX-M-3, blaCTX-M-14,  
blaCTX-M-15,  blaCTX-M-24,  
blaCTX-M-27 
China 2010 Yu FY. et al. 
K. pneumoniae rmtB blaCTX-M-15 Turkey 2010 Berçot et al. 
E. coli armA, rmtB blaCTX-M-15 Australia 2010 Poirel et al. 
Salmonella enterica armA blaCTX-M-15 Algeria 2011 Bouzidi et al. 
A. baumanii armA blaPER-7 France 2011 Bonnin et al. 
E. coli armA, rmtB blaCTX-M-15 France 2011 Poirel et al. 
E. coli armA blaCTX-M-15 Spain 2011 Solé et al. 
E. coli rmtB blaCTX-M-15 USA 2011 Tian et al. 
Enterobacteriaceae rmtB blaCTX-M-9,  blaCTX-M-14,  blaCTX-M-27, blaCTX-M-65 
China 2011 Deng et al. 
Enterobacteriaceae armA, rmtB blaCTX-M-15,  blaSHV-12 
Serbia, 
Pakistan 2011 Bogaerts et al. 
S. enterica Gambia armA blaCTX-M-3 France 2011 Moissenet et al. 
S. enterica Infantis armA blaCTX-M-15 Algeria 2001 Naas et al. 
K. pneumoniae armA blaCTX-M-3 Sweden 2011 Samuelsen et al. 
K. pneumoniae armA blaCTX-M Poland 2011 Zacharczuk et al. 
E. coli armA, rmtB blaCTX-M-15 Bangladesh 2011 Poirel et al. 
K. pneumoniae armA blaCTX-M-14 China 2011 Lee et al. 
K. pneumoniae rmtC blaCTX-M-15 
Kenya, 
India 2011 Poirel et al. 
Enterobacteriaceae rmtD2 blaCTX-M Argentina 2011 Tijet et al. 
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- Association with other resistance determinants. 
 Among the acquired 16S rRNA MTs producers, multiple determinants 
conferring resistance to different antibiotic classes can be found. Other than those 
mechanisms encoded by genes that belong to the bacterial chromosome (i.e., 
resistance to rifampicin by target mutation), most of the resistance genes linked to 
the 16S rRNA MTs are located on plasmids or mobile elements. Hence, genetic 
platforms such as integrons facilitate the capture of several resistance genes in a 
single cassette. One example could be the Tn1548 in which armA is embedded; 
besides the macrolide resistance genes located downstream of armA, this 
transposon contains one class 1 integron with various resistance genes to 
sulfonamides, trimethoprim, or aminoglycosides (Gonzalez-Zorn et al., 2005a). 
Apart from the β-lactam and quinolone resistance genes previously described, it is 
common to detect the presence of genes conferring resistance to tetracycline (i.e., 
tet), macrolides (i.e., mel, mph2), chloramphenicol (i.e., cat), or even multiple 
S. enterica 
Paratyphi B armA blaCTX-M-3 China 2012 Du et al. 
E. coli rmtB 
blaCTX-M-3,  blaCTX-M-14,  
blaCTX-M-27, blaCTX-M-55,  
blaCTX-M-65 
China 2012 Hou et al. 
E. coli  rmtB blaCTX-M-15 China 2012 Li et al. 
K. pneumoniae, 
Enterobacter 
amnigenus 
rmtB blaCTX-M-3,  blaCTX-M-14,  blaSHV-12  
China 2012 Sheng et al. 
Enterobacteriaceae rmtC blaCTX-M-15 
New 
Zealand 2012 Williamson et al. 
K. pneumoniae rmtH blaCTX-M-15 Iraq 2013 O´Hara et al. 
K. pneumoniae rmtD, rmtG 
blaCTX-M-2,  blaCTX-M-15,  
blaCTX-M-59 
Brazil 2013 Bueno et al. 
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aminoglycoside modifying enzymes in 16S rRNA MTs produing-bacteria (Jiang et 
al., 2010; Sekizuka et al., 2011; Wachino and Arakawa, 2012; Dolejska et al., 
2013).     
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OBJECTIVES AND 
JUSTIFICATION  
  
 In the last decades, the rapidly growing emergence and spread of bacterial 
resistance to antibiotics, combined with a decreasing discovery of new effective 
molecules to combat bacterial infections, has turned antibiotic resistance into one 
of the major concerns for Public Health. Bacterial infections caused by MDR 
gram-negative bacilli have become one of the biggest obstacles in both hospitals 
and the community. As a matter of fact, 4 out of the 6 famous ESKAPE pathogens 
(described in the introduction section and recognized as one of the main threats of 
this century) are gram-negative bacilli.  
 Aminoglycosides are considered broad-spectrum antimicrobials that exhibit 
bactericidal activity against both gram-positive and gram-negative infections. This 
family of antibiotics is widely used in human and veterinary medicine, and they are 
still one of the most valuable weapons to combat infections caused by gram-
negative pathogens. They often constitute the treatment of choice for infections due 
to MDR strains. The recent emergence of the 16S rRNA methyltransferases in 
gram-negative bacteria, poses a serious problem regarding the efficacy of all 
clinically available aminoglycosides. 
 The objectives of this Doctoral Thesis are the identification and molecular 
characterization of aminoglycoside resistance methyltransferases in gram-negative 
bacteria from humans, animals, and food. This will contribute to a better 
understanding of the role that animals and food play in the transmission of these 
resistance determinants. Furthermore, it will lead to a deeper knowledge of the 
epidemiology and the genetic platforms involved in the mobilization of these 
genes. The monitoring and study of emerging resistance mechanisms is crucial if 
antibiotic resistance is to be delayed.  
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PUBLICATIONS  
  
This Doctoral Thesis is presented in publications format, and it consists of four 
works. Three of these works have been published in the journal Antimicrobial 
Agents and Chemotherapy (ISI 2012, Impact Factor: 4,565), and one of the works 
has been published in the Journal of Antimicrobial Chemotherapy (ISI 2012, 
Impact Factor: 5,338).   
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DISCUSSION  
 
1- Aminoglycoside resistance 16S rRNA methyltransferases: from the 
producer’s necessity to the pathogen’s advantage? 
 Acquired 16S rRNA MTs have recently emerged in gram-negative bacteria 
as a high-level resistance mechanism to aminoglycosides that mimics the one used 
by the aminoglycoside-producing bacteria to avoid the action of the antibiotic they 
generate. In the last decades, intrinsic 16S rRNA MTs have been thoroughly 
studied in aminoglycoside producers. Analysis of the known acquired MTs has 
revealed that they can be classified into two families, Arm and Pam, equivalent to 
the Kgm and Kam MTs families of the producers according to their methylation 
target in the 16S rRNA (Conn et al., 2009). Nevertheless, the exact origin of 
acquired 16S rRNA MTs still remains uncertain.    
 Perhaps, based on the target of methylation it would be logical to assume 
that the acquired MTs originated from the intrinsic MTs. However, a few indicators 
make such a statement doubtful. When comparing the amino acid sequence of the 
acquired MTs with that of the chromosomally-encoded MTs from the producers, it 
can be seen that less than 33% identity exists between them. In addition, after the 
identification of several acquired MTs, it was observed that their overall G+C 
content was low (Figure 13) compared to the MT genes from the actinomycetes 
(ranging between 64% and 72%), which suggests that the acquired MTs are 
unlikely to be derived from those of the producers (Liou et al., 2006). Gram-
negative bacteria bearing an acquired MT usually display a genomic G+C content 
lower than that of the actinomycetes. Furthermore, the average G+C content of the 
close genetic environment of certain acquired MTs genes, such as armA and rmtE, 
is even higher than the MT gene G+C content (Galimand et al., 2003; Davis et al., 
2010). However, genes with a G+C content close to that of their bacterial genome 
could have been integrated into it many years ago and adapted to the average total 
G+C content (Hayek, 2013), hence, the hypothesis that acquired MTs could 
originate from the producers cannot be entirely ruled out. It also has to be taken 
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into account that aminoglycoside resistance via methylation is not the only 
ribosomal target-based strategy found to avoid suicide in the producers (Cundliffe 
and Demain, 2010). Erm methyltransferases, responsible for macrolide resistance 
by methylating the 23S rRNA in the producers of macrolides (also actinomycetes), 
are expressed in a wide range of microorganisms including gram-positive species 
and phylogenetically remote gram-negative bacteria. It has been suggested that 
these macrolide resistance MTs in gram-positive (i.e. Staphylococcus spp.) and 
gram-negative (i.e. E. coli) bacteria are likely to have originated from a common 
ancestor in the producers a long time ago, despite the diversity of the codon usage 
(Arthur et al., 1987). Regarding this option, it would be interesting to analyse the 
presence of acquired aminoglycoside resistance MTs in gram-negative bacteria 
isolated a long time ago (prior to the late 90s) as well as to compare the G+C 
content of their genes to that of the recently described acquired MT genes.  
 
        
  
 
 Alternatively, the existence of gram-positive bacteria with a low genomic 
G+C content has been described, such as some species of the genus Bacillus, that 
produce small amounts of some aminoglycosides (i.e., Bacillus circulans naturally 
produces butirosin), making any of these producers a viable candidate as a source 
of acquired 16S rRNA MTs. For this reason, Liou et al. cloned and expressed 
Figure 13. Chart showing the G+C content (%) of the acquired 16S rRNA MT 
genes reported to date.   
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armA into Bacillus subtilis where it conferred a high-level aminoglycoside 
resistance (Liou et al., 2006). Another recent study confirmed that RmtC confers 
the high-level aminoglycoside resistance phenotype when cloned into B. subtilis 
and Staphylococcus aureus (Wachino et al., 2010). These assays further 
strengthened the hypothesis of low G+C content gram-positive bacteria as the 
origin of acquired MTs. Moreover, B. circulans is a bacterium found in soil that 
may be involved as an opportunistic pathogen in human infections. Thus, we 
wonder whether this microorganism is more related to gram-negative bacteria 
present in clinical settings and the commensal microbiota than to the environmental 
actinomycetes, which are rarely found to be pathogenic bacteria. To overcome this 
issue, it would be relevant to screen low G+C content aminoglycoside-producing 
bacteria, such as Bacillus spp, for possible aminoglycoside resistance MTs.  
 After considering that acquired AG resistance MTs might in fact derive 
from the producers, either the environmental Actinobacteria or the low G+C 
content gram-positive bacteria, a third option may be considered: could these MTs 
have originated from an endogenous 16S rRNA MT in gram-negative bacteria? It 
is well known that rRNA sequences adjacent to the nucleotides that interact with 
aminoglycosides at the 16S rRNA Helix 44, are targeted by several endogenous 
methyltransferases. These housekeeping modifications are believed to influence 
both the function and the structure of the ribosome (Decatur and Fournier, 2002), 
and these methyltransferases are highly conserved displaying a G+C content 
similar to that of the host bacterium (Gutierrez et al., 2013). Therefore, would it be 
possible that faced with an increasing aminoglycoside selective pressure, gram-
negative bacteria could have developed the ability of adapting an endogenous MT 
to methylate the residues G1405 or A1408 involved in aminoglycoside resistance? 
An in-depth comparative structural analyses of endogenous and acquired MTs 
would provide insight into the origin of acquired 16S rRNA MTs. 
 So far three possible origins of the acquired 16S rRNA MTs have been 
mentioned. However, we should not dismiss the idea of more than one origin, due 
to the low similarity between some of the acquired MTs. In any of these scenarios, 
all the acquired MTs could have evolved from a common ancestor or, on the 
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contrary, independently from each other. If we re-analyze the base usage of the 
acquired 16S rRNA MTs, it can be observed that the G+C content of armA, rmtA-
E, and npmA, is significantly lower than that of the last three reported MT genes, 
rmtF, rmtG, and rmtH (Figure 13). While rmtA, rmtB, and rmtD/D2 show a G+C 
content of 55-59%, similar to the average G+C content of many 
Enterobacteriaceae, the G+C content of armA, rmtC, rmtE, and npmA ranges from 
30% to 41%, which is even lower than that of their close genetic environment. 
Interestingly, these numbers match the average genomic G+C content of several 
Bacillus spp. strains (including B. circulans). In addition, the dendrogram formed 
with the acquired G1405 16S rRNA MTs suggests that they are clearly divided into 
two groups where ArmA, RmtC and RmtE constitute the first group (Figure 14). 
On the other hand, the higher G+C content of the newly identified MT genes 
(rmtF,67.5%; rmtG,60%; rmtH,61.2%) approaches that of the environmental 
actinomycetes, suggesting for these a direct origin from the producers is likely.  
                       
  
 
 In this work, the emergence and spread of the novel rmtF gene in India and 
the UK have been elucidated, as well as confirming the presence of rmtF in 
different plasmids and enterobacterial species. Thus, this MT possibly originated 
independently from other acquired MTs, jumped from the producers to 
Enterobacteriaceae some time ago and escaped unidentified. This is not surprising 
Figure 14. Dendrogram constructed with the acquired 16S rRNA MTs 
reported to date. The bar denotes genetic distance. Bootstrap values are 
the result of 1000 iterations.  
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if one takes into consideration that there were almost no screenings for acquired 
MTs in India prior to this study (where the strains were collected in 2010-2011). If 
at least some of these acquired MTs arose from an unrelated origin, this would 
indicate that novel acquired aminoglycoside resistance MTs might shortly emerge 
among clinical isolates. 
 
2. Current prevalence and distribution of acquired 16S rRNA MTs: tying up 
loose ends 
 This work has mentioned how the emergence of acquired 16S rRNA MTs 
among gram-negative pathogens was a sudden process of rapid development, and 
the available data regarding the epidemiology of these enzymes is increasing 
substantially. However, there are several issues that remain unclear and open the 
door for a number of questions.  
 Regarding the prevalence of this resistance mechanism, it is interesting to 
point out that ArmA and RmtB are very highly prevalent compared to the other 
methyltransferases. This could be explainedby the enhanced dissemination 
facilitated by the mobile elements carrying these genes. Other acquired MTs have 
only been isolated from a few isolates. For example, the novel RmtH has only been 
detected in a single isolate, but it must be taken into consideration that this is a 
recent report and further publications might appear in the coming years. This is not 
the case for the only acquired MT belonging to the Pam family, NpmA, which was 
reported in 2007 from a single E. coli strain, and despite conferring pan-
aminoglycoside resistance, it has not been isolated since then. NpmA confers 
resistance to 4,6-DOS, but also, a high-level resistance to the 4,5-DOS and 
apramycin (Wachino et al., 2007). Given the little usage of the 4,5-DOS AGs as 
compared to the 4,6-DOS, and the lack of apramycin utilization in human 
medicine, we wonder whether this would be related to the cessation of both NpmA 
spreading and the identification of novel acquired MTs of the A1408 residue. As 
apramycin is a non-absorbed oral antibiotic used mainly for the treatment of 
colibacillosis, salmonellosis and enteritis in poultry and livestock, further 
Discussion 
[Type the date]  
  144 
monitoring of N1-A1408 methyltransferases among veterinary samples would be 
pertinent. Indeed, this underlines antibiotic usage as a key factor for the 
dissemination and maintenance of resistance determinants.       
 RmtA prevalence and distribution is also worth mentioning. Regardless of 
its early identification, this acquired MT was only found in a few P. aeruginosa 
isolates from Japan, plus one P. aeruginosa strain from South Korea (Yokoyama et 
al., 2003; Yamane et al., 2007; Jin et al., 2009), until it was described in a K. 
pneumoniae from an Indian patient (Poirel et al., 2011b). Why have no reports of 
RmtA come up since then? In those P. aeruginosa strains where the rmtA genetic 
surroundings have been elucidated, the rmtA gene is found within a Tn5041 
variant. This transposon is well adapted to P. aeruginosa. Thus, it would be 
interesting both to further screen for the presence of rmtA in P. aeruginosa isolates 
as well as to determine the genetic environment of rmtA in K. pneumoniae. Perhaps 
this gene was spreading via the Tn5041 transposon and once it passed to K. 
pneumoniae, the dissemination of this transposon was unsuccessful among any 
bacteria other than P. aeruginosa.  
 The evolution of RmtC dissemination after its first identification is also 
worth mentioning, as for a long time it was thought to be present only in those 
Proteus mirabilis strains found in Japan and Australia (Wachino et al., 2006b; 
Zong et al., 2008), so it did not pose a considerable threat for serious infections. 
Nevertheless, since its discovery in Salmonella enterica isolates from the USA and 
the UK (Folster et al., 2009; Hopkins et al., 2010), there has been a noticeable 
increase in the number of publications regarding the appearance of this acquired 
MT among different bacterial species (Poirel et al., 2011c; Islam et al., 2012; 
Williamson et al., 2012). Interestingly, most of those S. enterica strains were 
isolated from patients that had recently travelled to India, and rmtC appeared to 
always be adjacent to an ISEcp1 mobile element. Furthermore, in this work, the 
presence of RmtC associated with RmtF and NDM-1 in Indian isolates is 
demonstrated, as well as in one UK isolate from a patient who had recently 
travelled to India. This geographical region seems to play a role as a reservoir for 
antibiotic resistance, especially if we take several factors into account, including 
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the lack of effective policies for the control of antibiotic usage. In addition, ISEcp1 
is likely to be responsible for the transposition and spreading of rmtC (Wachino et 
al., 2006a), therefore, we present a diagram (Figure 15) to explain and possibly 
predict the dissemination of RmtC, which has recently been increased and might be 
exponentially accelerated in the near future.  
 
 
 
 
 Similar events can be pointed out for each acquired 16S rRNA MT related 
to their geographical distribution. For instance, in a similar way as RmtA presence 
is limited to Asia, the acquired MTs RmtD and RmtD2 seem to be present only in 
South America, despite their first identification being a long time ago. RmtG, 
which has recently been found in Brazil (Bueno et al., 2013) shares the highest 
similarity with RmtD, and both methyltransferases have almost the same G+C 
content (60%). This strongly suggests that the RmtD and RmtG origin and 
dissemination are likely related, and monitoring RmtG in gram-negative bacteria 
Figure 15. Diagram representing the potential past and future dissemination pathways of 
RmtC. 
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worldwide in order to decipher whether its presence is confined to South America 
would be appropriate. The genetic environment of rmtD and rmtD2 has been 
elucidated for some strains, and ISCR14 may be involved in their dissemination. 
Thus, the lack of RmtD/D2 findings in the rest of the world is surprising, given the 
many migration movements that take place between continents nowadays. Most of 
the acquired MT producers are pathogenic bacteria isolated from inpatients and 
outpatients, but it is important to realize that many bacteria bearing an AG 
resistance MT might be undetected as they belong to the normal microbiota. 
Hence, we should consider the idea of also performing surveillance on healthy 
individuals as this would result in trustworthy data regarding the real prevalence 
and distribution of these resistance determinants.  
 These issues are a reminder that it is critical to not only detect new acquired 
MTs, but also to thoroughly analyze those traits associated with the known ones in 
order to gain the most knowledge. This will allow for a better understanding of the 
past, present, and possible future of this resistance mechanism.   
  
3. Animals, food, and the environment: supporting actors or main characters 
in a never-ending story?   
 Since our group identified ArmA in an Escherichia coli of porcine origin 
right after its first publication, non-human sources were dragged into the spotlight 
as possible vehicles for the dissemination of acquired 16S rRNA MTs. However, 
there were not many studies in the first years on samples other than those from 
clinical settings.  
 This work has contributed to a better understanding of the role that animals 
and food play in the emergence of acquired MTs. Primarily, we have confirmed the 
presence of the most prevalent acquired MT, ArmA, in a bacterium isolated from 
food for the first time. We have also detected this MT in K. pneumoniae ST11 
isolated from companion animals in Spain. RmtB was the only acquired MT 
previously found in bacteria collected from pets (Deng et al., 2011a). These 
findings are noteworthy, as K. pneumoniae ST11 is a pathogenic clone adapted to 
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humans and related to MDR phenotypes. The low detection of acquired MTs 
among bacteria from pets led us to think that companion animals were not 
ultimately responsible for this resistance determinant spreading. However, the 
successful colonization of different pets by a human-adapted clone, such as K. 
pneumoniae ST11, gives rise to consider companion animals as a potential vector 
for bacteria highly resistant to AGs. This might be promoted by the tight 
relationship between humans and pets, but also by the usage of nearly the same 
aminoglycosides for the treatment of companion animals and humans.  
 Most findings of an acquired 16S rRNA MT from food, animals or the 
environment do not suggest that these sources are the main cause for the MTs 
dissemination. For instance, the RmtD-producing strain from a Brazilian river 
(Fontes et al., 2011), and the RmtC positive Samonella isolated from food in the 
UK (Hopkins et al., 2010), were clonally related to those human strains previously 
described to carry RmtD in Brazil and RmtC in the UK, respectively. Moreover, 
the ArmA-producing S. enterica strain from Reunion Island reported in this work, 
was recovered from chicken meat sampled during a control by the retailer in a 
supermarket. Interestingly, no other MDR strain was detected from farm chickens 
during a surveillance study performed at that time in Reunion Island (Henry et al., 
2009). This strongly suggests that these cases are the result of a cross 
contamination from a human origin. However, different studies have reported that 
the widespread dissemination of RmtB in China is not only associated with 
livestock and farm animals, but livestock-farming environments, farm workers, and 
pets (Chen et al., 2007; Liu et al., 2008; Du et al., 2009; Deng et al., 2011a). 
Moreover, the prevalence rate of RmtB-producing bacteria from animals is much 
higher than that from clinical strains (Deng et al., 2013), contrary to the other 
acquired MTs. Around half of RmtB-positive isolates also harbour the 
fluoroquinolone resistance efflux pump QepA, and several studies have shown a 
link between both resistance determinants within the same mobile structure (Poirel 
et al., 2012). Due to the high usage of quinolones in animals in the last decades, 
this could be promoting a co-selection for RmtB, and in this particular case, animal 
sources would be the main transmission vector of this acquired MT.     
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 Therefore, depending on factors such as the association of different 
resistance determinants on the same mobile genetic structure, or the antibiotic 
stewardships in veterinary medicine, non-human sources could either be the 
principal vehicle of a particular 16S rRNA MT or just another route of 
transmission due to human contamination. Generally, it has been considered that 
food-producing animals play a more important role than pets in the transmission of 
antibiotic resistance. To clarify this, it would be interesting to sample owners of 
pets carrying MT-producing bacteria, or even pets of patients carrying MT-
producing bacteria, in order to better ascertain the role of companion animals in the 
dissemination of antibiotic resistance.        
 
4. Acquired 16S rRNA MTs in carbapenemase-producing bacteria (CPB): a 
global threat   
 We have previously mentioned that organisms producing acquired 
aminoglycoside resistance MTs are often multidrug resistant. Such bacteria 
currently pose one of the greatest risks to Public Health. The main antibiotic 
classes for the treatment of gram-negative bacterial infections are aminoglycosides, 
fluoroquinolones, and β-lactams. Therefore, the co-existence of mechanisms 
conferring resistance to these antibiotic families strongly limits the therapeutic 
options available. Moreover, the association of resistance determinants on the same 
plasmid is worrisome as they disseminate faster due to co-selection by different 
drugs.  
 Since their first identification, there has been a large association of AG 
resistance MTs with ESBLs, especially CTX-M-type enzymes (shown in Table 12 
in the introduction section). Monotherapy with broad-spectrum β-lactams, such as 
cefotaxime, was commonly used to treat gram-negative bacterial infections, and 
aminoglycosides became an alternative for the treatment of infections caused by 
ESBL-producing organisms. Therefore, bacteria co-producing AG resistance MTs 
and ESBLs became of concern in the last years. However, carbapenem-hydrolyzing 
Discussion 
[Type the date]  
  149 
β-lactamases, which slowly emerged in Enterobacteriaceae in the early 2000s, 
have recently become increasingly prevalent worldwide.    
        
Table 13. Associations of AG resistance MTs and carbapenemases published to date 
Acquired 16S 
rRNA MT  Carbapenemases References 
ArmA 
OXA-23-like, VIM-2, IMP-1, KPC-
2*, NDM-1*, OXA-24-like, OXA-
58-like, VIM-4, VIM-1, OXA-48*  
Doi et al., 2007; Lee et al., 2007; Kim et 
al., 2008; Gurung et al., 2010; Jiang et 
al., 2010; Karthikeyan et al., 2010; 
Zacharczuk et al., 2010; Bogaerts et al., 
2011; Karah et al., 2011; Ho et al., 2011; 
Poirel et al., 2011a; Samuelsen et al., 
2011; Sekizuka et al., 2011; Solé et al., 
2011; Sung et al., 2011; Dortet et al., 
2012; McGann et al., 2012; Dolejska et 
al., 2013; Tada et al., 2013c, This work 
RmtA NDM-1, VIM-2 Jin et al., 2009; Poirel et al., 2011b 
RmtB OXA-23-like, OXA-51-like, KPC-2*, NDM-1, NDM-8 
Galani et al., 2012; Poirel et al., 2011b; 
Sheng et al., 2012; Tada et al., 2013b, 
2013c; This work 
RmtC NDM-1 Poirel et al., 2011c; This work 
RmtD/D2 SPM-1, KPC-2* Doi et al., 2007c, 2007d; Fontes et al., 2011; Bueno et al., 2013 
RmtE − − 
RmtF NDM-1* This work 
RmtG KPC-2* Bueno et al., 2013 
RmtH − − 
NpmA − − 
* Carbapenemase and MT genes co-harbored by the same plasmid 
          
 The clinically most important carbapenemases in gram-negative pathogens 
are the class A enzymes of the KPC type, characteristic of MDR K. pneumoniae; 
the zinc-dependent class B metallo-β-lactamases (MBLs), represented mainly by 
the VIM, IMP, and NDM types; and the class D carbapenem-hydrolyzing OXA 
enzymes (Tzouvelekis et al., 2012). As carbapenemases inactivate almost all 
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available β-lactams, if aminoglycoside activity is lost due to 16S rRNA 
methylation, we are facing a real threat with nearly no therapeutic tools. 
Fortunately, the appearance of AG resistance MTs within CPB was a relatively rare 
phenomenon until the extensive worldwide spread of the NDM-1 enzyme, firstly 
described in 2009, when it was repeatedly documented (Table 13). In fact, most 
publications discussing AG resistance 16S rRNA MTs in CPB are related to NDM-
1 MBL. There is no characteristic association of a particular carbapenemase and an 
AG resistance MT with the exception of RmtD, which is generally described in 
SPM-1-producing P. aeruginosa from Brazil (Table 13).    
 Besides the importance of focusing on this emerging concern, it is 
necessary to not forget the relevance of ESBLs regardless of their high prevalence 
and dissemination, in particular the scarcely reported enzymes, such as the VEB 
ESBLS. These enzymes confer resistance to aztreonam, the only β-lactam not 
hydrolyzed by NDM-1. In this work, we have described the presence of a novel 
VEB enzyme variant, VEB-5, in clinical ArmA-producing S. enterica from the 
UK. Thus, resistance to AG and all β-lactams except carbapenems converge in 
highly pathogenic bacteria like Salmonella spp. Moreover, the armA and blaVEB-5 
genes were located on the same plasmid. This indicates a strong likelihood for the 
emergence of gram-negative pathogens resistant to all existing β-lactams due to the 
co-expression of NDM and VEB enzymes. Therefore it is crucial to simultaneously 
pay attention to the trend of associations between these resistance determinants.  
 In addition, with this work we have contributed to the deciphering of the 
growing emergence of AG resistance MTs in NDM-1-producing pathogens in 
India, one of the countries believed act as the epicentre of the NDM-1 epidemic 
(Livermore et al., 2011b).  
 In our study, several enterobacteria isolated in the UK co-produce NDM-1 
and the novel RmtF. Although this topic has raised controversy, there are some 
findings that clearly point out certain geographical regions of the Indian 
subcontinent as the origin for this emergence in the UK. Firstly, in the same year 
there is a higher prevalence of rmtF-bearing strains isolated from India than the 
UK. Out of the six UK isolates producing RmtF and NDM-1, four were isolated 
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from patients who had recently travelled to India, and out of these four strains, one 
shared 88% genetic similarity with an Indian isolate. Furthermore, K.pneumoniae 
isolates carrying NDM-1 and diverse AG methyltransferases, including RmtF, have 
just now been published (Tada et al., 2013a). These bacteria were isolated from 
inpatients at a Teaching Hospital in Kathmandu, Nepal, in 2012. Interestingly, the 
RmtF-bearing bacteria from our study were collected during 2010 and 2011 at the 
Sanjay Gandhi Postgraduate Institute of Medical Sciences in Lucknow, India. This 
is a referral hospital that draws patients from most of the northern Indian states, 
mostly from the states of Uttar Pradesh and Bihar. These are the Indian regions 
geographically adjacent to Nepal (Figure 16).  
       
                        
 
 
        The sequence of an NDM-1-bearing plasmid, pKPX-1 (AN: AP012055) was 
recently published, mentioning a putative rRNA methyltransferase in the sequence 
annotation, and it turns out that this plasmid contains an rmtF gene. This strain 
came from a Taiwanese patient with a hospitalization history in New Delhi, India. 
In these strains the immediate genetic environment downstream of rmtF consists of 
an insE transposase with a duplicated oriIS ISCR5 upstream of the MT gene, as it 
was also found in our work. Therefore it seems that rmtF could be spreading out 
mainly through transposition by this mobile element. These results constitute more 
Figure 16. Map showing the Indian states where the RmtF-
bearing strains from this study were isolated.      
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evidence of what has recently been suspected, as it is frequent to detect NDM-1-
positive strains from patients with travel history to the Indian subcontinent. In 
addition, the currently increasing human migration from- and to- countries with 
poor policies regulating antibiotic usage might support this hypothesis.            
 Unfortunately there are not many possibilities to control the flow of these 
bacteria between countries, hence, it is extremely necessary to resolve the root of 
the problem by controlling AB use in those countries. It is striking to observe that, 
despite the increasing number of reports regarding the association of acquired MTs 
and carbapenemases, so far none of these identified bacteria were collected from 
animals. Only very recently has the emergence of CPB from farm animals been 
reported (Seiffert et al., 2013), possibly as a result of the reduced use of 
carbapenems in veterinary medicine. Currently the stage of carbapenem emergence 
in bacteria from animals resembles the early stages of ESBL dissemination, thus 
carbapenems should not be licensed for use in animals. However, the co-selection 
of CPB with other antibiotics used in veterinary medicine would still inflate the 
problem.  
 For this reason, it is not surprising that in 2012, the WHO focused its 
strategy on the five most important areas for the control of antibiotic resistance, 
which are: surveillance, rational use in humans, rational use in animals, infection 
prevention and control, and innovation. At the present stage, a global surveillance 
comprising the identification of known and novel resistance determinants, their 
molecular and epidemiological characterization, and the monitoring of resistance 
emergence to the latest therapeutic options, such as colistin and tigecycline, in MT-
positive CPB, is decisive. Not for nothing, we are already facing this problem, as 
tigecycline and colistin resistance was detected in four and two rmtF-bearing 
isolates, respectively, in this study.  
Conclusions/Conclusiones 
[Type the date]  
  155 
CONCLUSIONS/CONCLUSIONES  
 
 
First. ArmA, the most prevalent aminoglycoside resistance methyltransferase, is 
present in Salmonella enterica isolated from chicken meat in Reunion Island. This 
is the first report of ArmA in East Africa and from bacteria collected from food, 
which implies a novel route of spread for this resistance determinant. 
Primera. ArmA, la metiltransferasa de resistencia a aminoglucósidos más 
prevalente, está presente en Salmonella enterica aislada de carne de pollo en La 
Isla de Reunión. Esta es la primera identificación de ArmA en África del Este y en 
una bacteria de origen alimentario, lo que implica una nueva ruta de transmisión 
para este determinante de resistencia.    
 
 
 
Second. We have developed a method consisting of nine overlapping PCRs to 
amplify Tn1548, the genetic platform in which the armA gene was originally 
detected. Tn1548-like structures seem to accelerate the spread of armA among 
different plasmids and gram-negative bacterial species.  
Segunda. Hemos desarrollado un método de nueve PCRs solapantes para 
amplificar el Tn1548, la plataforma genética en la cual armA fue identificado por 
primera vez. Distintas variantes del Tn1548 están acelerando la diseminación de 
armA a través de distintos plásmidos y especies de bacterias gram-negativas.      
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Third. We have identified a novel VEB enzyme, VEB-5, an ESBL responsible for 
high-level resistance to aztreonam in clinical Salmonella Worthington from the 
UK. Its coding gene is co-located with armA in pB1016, a conjugative IncA/C 
plasmid. This is the first association of ArmA with a VEB-type ESBL.  
Tercera. Hemos identificado VEB-5, una nueva ESBL que confiere alto nivel de 
resistencia a aztreonam, en aislados clínicos de Salmonella Worthington de Reino 
Unido. El gen de esta nueva enzima está localizado junto con armA en pB1016, un 
plásmido conjugativo IncA/C. Esta es la primera asociación de ArmA con una 
BLEE de tipo VEB.   
 
 
 
Fourth. RmtF is a new member of the 16S rRNA methyltransferases family that 
confers high-level resistance to aminoglycosides via the methylation of nucleotide 
G1405 in the 16S rRNA. This protein, of 260 amino acids, shares 46% amino acid 
identity with its closest methyltransferase, RmtD.  
Cuarta. RmtF es un nuevo miembro de la familia de las metiltransferasas del 
ARNr 16S que confiere alto nivel de resistencia a aminoglucósidos al metilar el 
nucleótido G1405 en el ARNr 16S. Esta proteína, de 260 aminoácidos, comparte 
un 46% de identidad aminoacídica con la metiltransferasa más cercana, RmtD.  
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Fifth. The novel aminoglycoside resistance determinant, RmtF, is disseminating on 
diverse plasmids among clinical Enterobacteriaceae in India and the UK. These 
bacteria often co-produce a second methyltransferase as well as other emerging 
resistance mechanisms, such as NDM carbapenemase.  
Quinta. El nuevo determinante de resistencia a aminoglucósidos RmtF, se está 
diseminando en Enterobacterias de origen clínico de India y de Reino Unido, 
localizado en diversos plásmidos. Estas bacterias a menudo expresan una segunda 
metiltransferasa, así como otros mecanismos de resistencia emergentes, como la 
carbapenemasa NDM.   
 
 
 
Sixth. ArmA has been detected in bacteria isolated from companion animals for 
the first time. It is carried with QnrB4 and DHA-1 determinants in Klebsiella 
pneumoniae ST11, which is a human epidemic clone. This suggests the existence 
of a new reservoir for clinical multidrug-resistant K. pneumoniae.  
Sexta. Hemos detectado ArmA por primera vez en bacterias aisladas de animales 
de compañía. Se trata de Klebsiella pneumoniae ST11, un clon epidémico en 
humanos que, además de ArmA, porta los determinantes QnrB4 y DHA-1. Este 
hallazgo supone un nuevo reservorio para K. pneumoniae multirresistentes de 
origen clínico.  
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